WO2012074117A1 - 効率的な人工多能性幹細胞の樹立方法 - Google Patents
効率的な人工多能性幹細胞の樹立方法 Download PDFInfo
- Publication number
- WO2012074117A1 WO2012074117A1 PCT/JP2011/077992 JP2011077992W WO2012074117A1 WO 2012074117 A1 WO2012074117 A1 WO 2012074117A1 JP 2011077992 W JP2011077992 W JP 2011077992W WO 2012074117 A1 WO2012074117 A1 WO 2012074117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pathway
- kinase
- ras
- family member
- cells
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to a method for improving the establishment efficiency of artificial pluripotent stem (hereinafter also referred to as iPS) cells and a drug therefor. More specifically, the present invention relates to a method for improving iPS cell establishment efficiency using a Ras family member, and an iPS cell establishment efficiency improving agent comprising a Ras family member as an active ingredient.
- iPS artificial pluripotent stem
- Non-Patent Document 1 introduced the Oct3 / 4, Sox2, Klf4 and c-Myc genes into a fibroblast derived from a reporter mouse knocked in with a neomycin resistance gene at the Fbx15 locus and forced expression. IPS cells were induced.
- Non-Patent Document 2 created a transgenic mouse in which a green fluorescent protein (GFP) and a puromycin resistance gene were incorporated into the locus of Nanog whose expression was more restricted to pluripotent cells than Fbx15.
- GFP green fluorescent protein
- IPS cells whose gene expression and epigenetic modification are almost the same as those of embryonic stem (ES) cells by forcibly expressing the above 4 genes in fibroblasts derived from the mice and selecting puromycin-resistant and GFP-positive cells (Nanog iPS cells) was successfully established. Thereafter, it was revealed that iPS cells can also be produced by three factors excluding the c-Myc gene (Non-patent Document 3). Furthermore, Takahashi et al. (Non-Patent Document 4) succeeded in establishing iPS cells by introducing the same 4 genes as in mice into human skin-derived fibroblasts. On the other hand, Yu et al.
- Non-Patent Document 5 produced human iPS cells using Nanog and Lin28 instead of Klf4 and c-Myc. Thus, it was shown that by introducing a specific factor into a somatic cell, an iPS cell that is inferior to an ES cell in differentiation pluripotency can be produced in humans and mice.
- iPS cell establishment efficiency is still low.
- three factors (Oct3 / 4, Sox2, Klf4) are introduced into somatic cells except for c-Myc, which is suspected to be tumorigenic in tissues and individuals differentiated from iPS cells.
- c-Myc which is suspected to be tumorigenic in tissues and individuals differentiated from iPS cells.
- Ras which is a low molecular weight GTPase, controls proliferation and differentiation in many cells. Ras usually exists as an inactivated form bound to GDP, but dissociates GDP by stimulating growth factors, etc., binds to GTP, changes to an activated form, and transmits a signal downstream through the target factor .
- Ras target factors Raf, phosphatidylinositol 3-kinase (PI3 kinase), Ral Guanine nucleotide ExchangingalFactor (RalGEF) and the like are known. Ras constitutively activated point mutations have been reported in various human cancer cells, and the failure of Ras protein function due to abnormal downstream signals of these target factors is one of the important steps in cell canceration. Has been speculated.
- Non-Patent Document 6 identified a gene homologous to other Ras genes that is specifically expressed in embryonic stem cells (ES cells) and named it ERas. ERas has only about 40% homology with other Ras as a whole, but the five guanine nucleotide-binding domains (G1-G5) essential for Ras function are highly conserved and required for membrane localization. And Cax motif (C: cysteine, a: aliphatic amino acid, x: any amino acid).
- An object of the present invention is to provide a means for improving the establishment efficiency of iPS cells, and to provide an efficient method of producing iPS cells using the same.
- the present inventors have found that in the nuclear reprogramming process of somatic cells, an activated Ras family member, its target factor or its related factor, PI3 kinase, RalGEF, It was clarified that the establishment efficiency of iPS cells can be remarkably increased by increasing the level of Raf, AKT family member, Rheb, TCL1 or S6K activated molecule.
- the present invention is as follows.
- a method for improving the establishment efficiency of induced pluripotent stem cells comprising the group consisting of Ras family member, PI3 kinase, RalGEF, Raf, AKT family member, Rheb, TCL1 and S6K in the nuclear reprogramming process of somatic cells Increasing the level of an activated form of one or more proteins selected from.
- [2] comprising contacting a somatic cell with one or more factors selected from the group consisting of a Ras family member, PI3 kinase, RalGEF, Raf, AKT family member, Rheb, TCL1 and S6K, and nucleic acids encoding them The method described in [1] above.
- [3] The method described in [2] above, wherein the Ras family member, PI3 kinase, RalGEF, Raf, AKT family member and S6K are constitutively activated.
- the Ras family member is selected from the group consisting of ERas, HRas, NRas and KRas.
- the Ras family member constitutively activates one or more signaling pathways selected from the PI3 kinase pathway, Ral pathway and MAP kinase pathway.
- An induced pluripotent stem cell comprising a factor selected from the group consisting of a Ras family member, PI3 kinase, RalGEF, Raf, AKT family member, Rheb, TCL1 and S6K, and nucleic acids encoding them. Establishment efficiency improver.
- Ras family member is selected from the group consisting of ERas, HRas, NRas and KRas.
- the Ras family member constitutively activates one or more signal transduction pathways selected from the PI3 kinase pathway, Ral pathway and MAP kinase pathway.
- the Ras family member constitutively activates the PI3 kinase pathway and / or the Ral pathway.
- [20] One or more factors selected from the group consisting of a nuclear reprogramming substance and a Ras family member, PI3 kinase, RalGEF, Raf, AKT family member, Rheb, TCL1 and S6K, and nucleic acids encoding them in a somatic cell
- a method for producing induced pluripotent stem cells comprising contacting [21] The method described in [20] above, wherein the Ras family member, PI3 kinase, RalGEF, Raf, AKT family member and S6K are constitutively activated.
- Ras family member is selected from the group consisting of ERas, HRas, NRas, and KRas.
- the Ras family member constitutively activates one or more signaling pathways selected from the PI3 kinase pathway, the Ral pathway, and the MAP kinase pathway.
- the Ras family member constitutively activates the PI3 kinase pathway and / or the Ral pathway.
- the nuclear reprogramming substance is selected from the group consisting of Oct family members, Sox family members, Klf4 family members, Myc family members, Lin family members and Nanog, and nucleic acids encoding them.
- the nuclear reprogramming substance is Oct3 / 4, Klf4, Sox2, and c-Myc or L-Myc and / or Nanog and / or Lin28 or Lin28B, or a nucleic acid encoding them.
- [32] comprising a factor selected from the group consisting of Ras family member, PI3 kinase, RalGEF, Raf, AKT family member, Rheb, TCL1 and S6K, and nucleic acids encoding them, and a nuclear reprogramming substance An inducer of induced pluripotent stem cells.
- Ras family member, PI3 kinase, RalGEF, Raf, AKT family member and S6K are constitutively activated.
- the agent described in [32] or [33] above, wherein the Ras family member is selected from the group consisting of ERas, HRas, NRas and KRas.
- the nuclear reprogramming substance is selected from the group consisting of an Oct family member, a Sox family member, a Klf4 family member, a Myc family member, a Lin family member and Nanog, and nucleic acids encoding them.
- induced pluripotent stem cells Use of the method according to claim 1, wherein the factor is brought into contact with a somatic cell together with a nuclear reprogramming substance.
- iPS cells Can be remarkably improved, and is particularly useful for iPS cell induction by three factors other than c-Myc, which has conventionally had a low establishment efficiency.
- FIG. 1 is a graph showing the results of Example 1.
- the vertical axis shows the fold change (Fold change) of the number of iPS colonies when the number of colonies obtained by introducing 4 genes of Oct3 / 4, Sox2, Klf4 and c-Myc is 1 (Red in the figure) .
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 2 is a graph showing the results of Example 2.
- the vertical axis shows the fold change (Fold change) of the number of iPS colonies when the number of colonies obtained by introducing 4 genes of Oct3 / 4, Sox2, Klf4 and c-Myc is 1 (Red in the figure) .
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 3 is a graph showing the results of Example 3. The left figure shows the results using Tig-120 cells, and the right figure shows the results using 1616 cells. In the figure, the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 4 is a graph showing the results of Example 4.
- the vertical axis shows the fold change (Fold change) of the number of iPS colonies when the number of colonies obtained by introducing 4 genes of Oct3 / 4, Sox2, Klf4 and c-Myc is 1 (Red in the figure) .
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 5 is a graph showing the results of Example 5. In the figure, the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 6 is a graph showing the results of Example 6.
- the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2, Klf4, and c-Myc genes with each gene shown on the horizontal axis.
- FIG. 7 is an alkaline phosphatase-stained image of an iPS cell colony showing the results of Example 7. Each number represents the number of iPS cell colonies.
- FIG. 8 is a graph showing the results of Example 8. In FIG. 8A, the vertical axis represents the number of iPS cell colonies.
- the horizontal axis shows the Oct3 / 4, Sox2 and Klf4 genes and twice the amount of Mock, Mock and Myr-AKT1, Mock and c-MYC shRNA, Myr-AKT1 and c-MYC shRNA, or Myr-AKT1 and GSK3 ⁇ S9A. Indicates a combination.
- the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2 and Klf4 genes with each gene shown on the horizontal axis.
- FIG. 9 is a graph showing the results of Example 9. In the figure, the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2 and Klf4 genes with each gene shown on the horizontal axis.
- FIG. 10 is a graph showing the results of Example 10.
- the vertical axis represents the number of iPS cell colonies.
- the horizontal axis represents the combination of the Oct3 / 4, Sox2 and Klf4 genes with each gene shown on the horizontal axis.
- FIG. 11 is a graph and a photograph showing the results of Example 11.
- the vertical axis represents the number of iPS cell colonies
- the horizontal axis represents the combination of the Oct3 / 4, Sox2 and Klf4 genes in the presence or absence of c-Myc shRNA and the respective genes shown on the horizontal axis.
- FIG. 11B shows intracellular c-Myc, p-AKT (phosphorylated AKT), AKT when Mock, Myr-AKT1, Rheb, S6K1 T389E or p53 shRNA was introduced into human-derived skin fibroblasts, respectively.
- the results of measuring the expression of p-S6K1 (phosphorylated S6K1), S6K1, p-TSC2 (phosphorylated TSC2) and TSC2 by the Western blot method are shown.
- FIG. 12 is a graph showing the results of Example 12.
- FIG. 12A shows the result of introduction into human-derived skin fibroblasts, where the vertical axis indicates the number of iPS cell colonies.
- the horizontal axis shows the combination of the Oct3 / 4, Sox2 and Klf4 genes in the presence or absence of p53 shRNA and the genes shown on the horizontal axis.
- FIG. 12B shows the result of introduction into human-derived skin fibroblasts, where the vertical axis indicates the number of iPS cell colonies.
- the horizontal axis shows the combination of the Oct3 / 4, Sox2 and Klf4 genes in the presence or absence of GLIS1 and each gene shown on the horizontal axis.
- FIG. 12C shows the result of introduction into human-derived dental pulp cells, where the vertical axis indicates the number of iPS cell colonies.
- the horizontal axis shows the combination of the Oct3 / 4, Sox2 and Klf4 genes in the presence or absence of p53 shRNA and the genes shown on the horizontal axis, and Oct3 / 4, Sox2 and Klf4 in the presence or absence of GLIS1.
- a combination of a gene and each gene shown on the horizontal axis is shown.
- the present invention relates to an activated Ras protein, an activated target factor thereof, a downstream signal factor of the activated Ras target factor, or an intracellular activator of the signal.
- a method for improving iPS cell establishment efficiency by increasing the level Means for increasing the intracellular level of the activated Ras protein, the activated target factor thereof, the downstream signal factor of the activated Ras target factor or the activator of the signal are not particularly limited.
- a protein that is a member of Ras family, PI3 kinase, RalGEF or Raf that is a target factor thereof, a downstream signal factor of a target factor of Ras or an AKT family member that is an activator of the signal, Rheb, TCL1 or S6K, or Examples include a method of contacting a somatic cell with an encoding nucleic acid, a substance that promotes a reaction that converts Ras protein into an activated form, or a substance that inhibits a reaction that converts Ras protein into an inactivated form.
- the present invention also provides iPS cells by bringing the substance and the nuclear reprogramming substance into contact with the somatic cells.
- a manufacturing method is provided.
- iPS cells cannot be established only with a nuclear reprogramming substance, and iPS cells are also established by increasing the level of activated Ras protein, etc. Treat as what you want.
- Somatic cell source Somatic cells that can be used as a starting material for producing iPS cells in the present invention are germ cells derived from mammals (eg, humans, mice, monkeys, cows, pigs, rats, dogs, etc.). May be any cell other than, for example, keratinized epithelial cells (eg, keratinized epidermal cells), mucosal epithelial cells (eg, epithelial cells of the tongue surface layer), exocrine glandular epithelial cells (eg, mammary cells), Hormone-secreting cells (eg, adrenal medullary cells), cells for metabolism and storage (eg, hepatocytes), luminal epithelial cells that make up the interface (eg, type I alveolar cells), luminal epithelium of inner chain vessels Cells (eg, vascular endothelial cells), ciliated cells with transport ability (eg, airway epithelial cells), cells for extracellular matrix secretion (eg, fibroblasts,
- undifferentiated progenitor cells including somatic stem cells
- final differentiated mature cells It can be used as the source of somatic cells in the invention.
- tissue stem cells such as neural stem cells, hematopoietic stem cells, mesenchymal stem cells, and dental pulp stem cells.
- the mammalian individual from which somatic cells are collected there are no particular restrictions on the mammalian individual from which somatic cells are collected.
- the patient or the HLA gene is used from the viewpoint that no rejection occurs. It is particularly preferred to collect somatic cells from another person of the same or substantially the same type.
- the HLA genotype is “substantially identical” means that cells obtained by inducing differentiation from iPS cells derived from the somatic cells by using immunosuppressive agents are transplanted into patients. Means that the HLA genotype matches to the extent that can be engrafted.
- genotypes of the main HLA for example, 3 loci of HLA-A, HLA-B and HLA-DR, or 4 loci plus HLA-C
- the genotypes of the main HLA for example, 3 loci of HLA-A, HLA-B and HLA-DR, or 4 loci plus HLA-C
- the genotypes of the main HLA for example, 3 loci of HLA-A, HLA-B and HLA-DR, or 4 loci plus HLA-C
- iPS cells are used as a source of screening cells for evaluating the patient's drug sensitivity and the presence or absence of side effects. It is desirable to collect somatic cells from others who have the same genetic polymorphism that correlates with side effects.
- Somatic cells isolated from mammals can be pre-cultured in a medium known per se suitable for culturing according to the type of cells prior to being subjected to the nuclear reprogramming step.
- a medium known per se suitable for culturing according to the type of cells prior to being subjected to the nuclear reprogramming step.
- Examples of such a medium include a minimum essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, 199 medium, and F12 medium containing about 5 to 20% fetal calf serum. It is not limited to.
- MEM minimum essential medium
- DMEM Dulbecco's modified Eagle medium
- RPMI1640 RPMI1640 medium
- 199 medium 199 medium
- F12 medium containing about 5 to 20% fetal calf serum.
- an introduction reagent such as a cationic liposome is used.
- Ras protein an activated molecule of the target factor, a substance that increases the level of the downstream signal factor of the Ras target factor or the activator of the signal
- “increases the level of the activated Ras protein” The “substance” may be any substance as long as it can increase the level of protein existing as an activated form (GTP-binding form) in one or more proteins belonging to the Ras family.
- the “substance that increases the level of an activated Ras protein target factor” means one or more factors of the three Ras protein target factors of PI3 kinase, RalGEF and Raf, preferably one or two factors Any substance can be used as long as it can increase the intracellular level of the activated form of PI3 kinase and / or RalGEF. That is, PI3 kinase, RalGEF or Raf or a nucleic acid encoding the same, or a localization factor that recruits these intracellular target factors to the cell membrane, for example, an activated Ras protein, is also referred to as “activated form” in the present specification. Substances that increase the level of Ras protein target factor.
- the “substance that increases the level of a downstream signal factor of Ras target factor or an activator of the signal” refers to a factor of further downstream signal of Ras protein target factor or an AKT family that is an activator of this signal
- the Ras protein its target factor or an activation type molecule of a downstream signal factor of the Ras target factor, and substances that increase the level of the signal activator, and are referred to as “the establishment efficiency improvement factor of the present invention” There is.
- Ras family member refers to Ras subfamily proteins identified among the Ras subfamily proteins identified by primary structural homology with HRas, KRas, and NRas identified as proto-oncogenes.
- preferred Ras family members include, but are not limited to, HRas, KRas, NRas, ERas and the like.
- NRas protein examples include mouse NRas (RefSeqNRAccession No. NP_035067) consisting of the amino acid sequence represented by SEQ ID NO: 10, human NRas (RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 12).
- NP_002515 or orthologs thereof in other mammals, as well as their natural allelic variants, polymorphic variants, splicing variants, natural and artificial activated variants, and the like.
- heterologous NRas can also be used.
- ERas protein examples include mouse ERas (RefSeqERAccession No. NP_853526) consisting of the amino acid sequence represented by SEQ ID NO: 14, and human ERas (RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 16).
- NP_853510 mouse ERas (RefSeqERAccession No. NP_853526) consisting of the amino acid sequence represented by SEQ ID NO: 14, and human ERas (RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 16).
- NP_853510 mouse ERas
- human ERas RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 16
- NP_853510 or its orthologs in other mammals, as well as their natural allelic variants, polymorphic variants, and splicing variants.
- heterologous ERas can also be used.
- the amino acid identity between human HRas and human KRas in this region is about 95%, and the amino acid identity between human HRas and human NRas is about 92%.
- five domains (G1 to G5) involved in binding to guanine nucleotides and effector domains involved in binding to target factors are particularly well conserved.
- the 4 amino acid residues at the C-terminal are called Caax motif (C: cysteine, a: aliphatic amino acid, x: any amino acid; SEQ ID NO: 17) It undergoes post-translational modification and a farnesyl group is added to the cysteine residue, followed by cleavage of the terminal 3 amino acids and methyl esterification of the newly exposed C-terminal cysteine. Ras protein binds strongly to the inner surface of the cell membrane by such lipid modification.
- Caax motif C: cysteine, a: aliphatic amino acid, x: any amino acid; SEQ ID NO: 17
- Ras proteins such as HRas, KRas, and NRas
- Ras proteins usually exist as inactivated forms bound to GDP, and are converted to activated forms bound to GTP when receiving signals from upstream, but various cancers
- Constantly activated Ras mutants have been isolated from cells, and numerous amino acid substitutions contributing to constitutive activation have been reported.
- the level of activated Ras protein can be increased efficiently.
- a mutant in which the 12th glycine of H-, K-, and N-Ras is replaced with valine is able to pass all three signaling pathways downstream of Ras (PI3 kinase pathway, Ral pathway, and MAP kinase pathway).
- Human and mouse ERas share about 40% homology with HRas as a whole, but G1 to G5 essential for Ras function, effector domain, and Caax motif necessary for membrane localization are conserved.
- G1 to G5 essential for Ras function, effector domain, and Caax motif necessary for membrane localization are conserved.
- 59th alanine, and 63rd glutamic acid of H-, K-, and N-Ras if any one of them is substituted with another amino acid, it becomes a constitutively activated form.
- three amino acids are different from other Ras, and it is known to constitutively activate the PI3 kinase pathway among the three signal transduction pathways downstream of Ras.
- the constitutively activated Ras protein used in the present invention is capable of constitutively activating at least one of the three signal transduction pathways downstream of Ras (PI3 kinase pathway, Ral pathway, and MAP kinase pathway).
- PI3 kinase pathway PI3 kinase pathway
- Ral pathway PI3 kinase pathway
- MAP kinase pathway PI3 kinase pathway
- Ras proteins that constitutively activate the PI3 kinase pathway and / or Ral pathway include ERas, H-, K- or N-Ras 12th glycine substituted with valine, and 37th glutamic acid Is a mutated glycine, or a double mutant in which the 40th tyrosine is replaced with a cysteine, but is not limited thereto.
- the Ras protein used in the present invention is preferably constitutively inactive in both the PI3 kinase pathway and the Ral pathway unless any of the three signal transduction pathways downstream of Ras is constitutively inactivated.
- 1 to 2 or more preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to a number (5, 4, 3, 2) in the amino acid sequence of any of the above Ras proteins, It may be a protein comprising an amino acid sequence in which a single amino acid is substituted, deleted, inserted or added.
- Ras target factor (effector) examples include PI3 kinase, RalGEF and Raf.
- the PI3 kinase in the present invention is a class IA PI3 kinase that is a target factor of Ras, and includes a p110 catalytic subunit (having three isoforms of ⁇ , ⁇ , and ⁇ ) and a regulatory subunit (p85 ⁇ , p85 ⁇ , p55 ⁇ , and the like) There are splicing variants).
- Preferred examples of the p110 protein include, for example, mouse p110 ⁇ (RefSeq Accession No. NP_032865) consisting of the amino acid sequence represented by SEQ ID NO: 19, human p110 ⁇ (RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 21) NP_006209), mouse p110 ⁇ (RefSeq Accession No. NP_083370), human p110 ⁇ (RefSeq Accession No. NP_006210), mouse p110 ⁇ (RefSeq Accession No. NP_0010250058), human p110 ⁇ (RefSeq Accession No.
- NP_005017 NP_005017
- NP_005017 NP_005017
- p110 p110
- a heterologous p110 can also be used.
- RalGEF protein examples include mouse RalGDS (RefSeqGAccessionRefNo. NP_033084) consisting of the amino acid sequence represented by SEQ ID NO: 23, and human RalGDS (RefSeq Accession No consisting of the amino acid sequence represented by SEQ ID NO: 25).
- NP_006266 mouse Rgl (RefSeq Accession No. NP_058542), human Rgl (RefSeq Accession No. NP_055964), mouse Rlf / Rgl2 (RefSeq Accession No. NP_033085), human Rlf / Rgl2 (RefSeq Accession No. NP_033085), human Rlf / Rgl2 (RefSeq Accession No.
- NP_0047 Orthologs thereof in mammals, natural allelic variants, polymorphic variants, splicing variants, natural and artificial activated variants, and the like. Depending on the animal species of the somatic cell to be introduced, it is desirable to use the same type of RalGEF, but it is also possible to use a heterologous RalGEF.
- Raf protein examples include, for example, mouse c-Raf consisting of the amino acid sequence represented by SEQ ID NO: 27 (RefSeq Accession No. ⁇ NP_084056), human c-Raf consisting of the amino acid sequence represented by SEQ ID NO: 29 (RefSeq Accession No. NP_002871), mouse A-Raf (RefSeq Accession No. NP_033833), human A-Raf (RefSeq Accession No. NP_001645), mouse B-Raf (RefSeq Accession No. NP_647455), human B-Raf (RefSeq Accession No.
- NP — 004324 or orthologs thereof in other mammals, as well as their natural allelic variants, polymorphic variants, splicing variants, natural and artificial activated variants, and the like.
- heterologous Raf can also be used.
- Ras target factors such as PI3 kinase, RalGEF, and Raf are activated by localizing on the inner surface of the cell membrane through binding to activated Ras, and activate downstream signal transduction pathways. Therefore, by introducing a constitutively activated mutant of these target factors into somatic cells, the level of the activated Ras target factor can be increased efficiently.
- Ras target factor is activated by localizing to the membrane, so that by adding a membrane localization signal sequence to the N-terminus or C-terminus of the target factor, constitutive activation of the target factor Type mutants can be made.
- a myristoylated signal sequence for example, myristoylated signal sequence ⁇ (MGSSKSKPKDPSQRRRRIRT; SEQ ID NO: 30) derived from c-Src
- MGSSKSKPKDPSQRRRRIRT SEQ ID NO: 30
- a Caax motif to the C-terminus (eg, PI3K-CaaX of Example 3, RalGDS-Caax, Raf-CaaX, etc. of Example 4) can do.
- constitutively activated mutants include, for example, a PI3 kinase mutant in which the histidine at position 1047 of p110 ⁇ is replaced with arginine, a mutant PI3 kinase in which the 545th glutamic acid of p110 ⁇ is replaced with lysine, and 227 of p110 ⁇ .
- PI3 kinase mutant in which the second lysine was replaced with glutamic acid
- PI3 kinase mutant lacking 108 amino acids (regulatory subunit binding domain) on the N-terminal side of p110, 305 amino acids on the N-terminal side of c-Raf (Ras Raf mutant lacking (including binding domain)
- Raf mutant with B-Raf 600th valine substituted with glutamic acid Raf mutant with c-Raf 340th tyrosine substituted with aspartic acid, etc.
- it is not limited to these.
- the constitutively activated Ras target factor used in the present invention is preferably a constitutively activated mutant of PI3 kinase (p110) or RalGEF, specifically, Myr-PI3K used in Examples described later, PI3K-CaaX, RalGDS-CaaX, etc. are mentioned.
- the constitutively activated PI3 kinase used in the present invention constitutively activates the signal transduction pathway of the AKT pathway.
- the Ras target factor used in the present invention is preferably one or two or more in the amino acid sequence of any of the above Ras target factors, unless the signal transduction pathway downstream of the target factor is constitutively inactivated.
- a protein comprising an amino acid sequence in which 1 to 20, more preferably 1 to 10, more preferably 1 to several (5, 4, 3, 2) amino acids are substituted, deleted, inserted or added. May be.
- an amino acid sequence having 80% or more, preferably 90% or more, more preferably 95% or more, further preferably 97% or more, particularly preferably 98% or more identity with the amino acid sequence of any of the above Ras proteins It may be a protein containing
- Ras target factor (effector) downstream signal factor used in the present invention includes AKT family members Rheb and S6K.
- Examples of the “activator of downstream signal of Ras target factor (effector)” include TCL1.
- the “AKT family member” is a protein identified as a homologous gene of v-Akt, which is a viral oncogene, and capable of transmitting a signal to activation of mTOR downstream thereof.
- AKT family members include, but are not limited to, AKT1, AKT2, AKT3, and the like.
- Preferred examples of the AKT protein include mouse Akt1 (RefSeq Accession No. NP_001159366) consisting of the amino acid sequence represented by SEQ ID NO: 35, human AKT1 (RefSeq Accession No. NP_001014432) consisting of the amino acid sequence represented by SEQ ID NO: 37, for example.
- Rheb protein examples include mouse Rheb (RefSeqSAccession No. NP_444305) consisting of the amino acid sequence represented by SEQ ID NO: 39, human RHEB consisting of the amino acid sequence represented by SEQ ID NO: 41 (RefSeq Accession No. NP_005605) Or their orthologs in other mammals, their natural allelic variants, polymorphic variants, splicing variants, natural and artificial activated variants, and the like. Depending on the animal species of the somatic cell to be introduced, it is desirable to use the same type of Rheb, but it is also possible to use a heterologous Rheb.
- TCL1 protein examples include mouse Tcl1 (RefSeq Accession No. NP_033363) consisting of the amino acid sequence represented by SEQ ID NO: 43, human TCL1A consisting of the amino acid sequence represented by SEQ ID NO: 45 (RefSeq Accession No. NP_001092195) Or their orthologs in other mammals, as well as their natural allelic variants, polymorphic variants, splicing variants (eg, RefSeq Accession No. NP_068801), natural and artificial activated variants, etc. It is done. Although it is desirable to use the same kind of TCL1 depending on the animal species of the somatic cell to be introduced, heterologous TCL1 can also be used.
- S6K protein examples include, for example, S6K (RefSeq Accession No. NP_001107806) consisting of the amino acid sequence represented by SEQ ID NO: 47, human S6K1 (RefSeq Accession No. NP_003152) consisting of the amino acid sequence represented by SEQ ID NO: 49, Or their orthologs in other mammals, their natural allelic variants, polymorphic variants, splicing variants (eg RefSeq Accession No. NP_082535), natural and artificial activated mutants, etc. .
- S6K RefSeq Accession No. NP_001107806
- human S6K1 RefSeq Accession No. NP_003152
- SEQ ID NO: 49 Or their orthologs in other mammals, their natural allelic variants, polymorphic variants, splicing variants (eg RefSeq Accession No. NP_082535), natural and artificial activated mutants, etc.
- AKT family members are activated by localizing on the inner surface of the cell membrane through binding to activated Ras, PI3 kinase, etc., and activate downstream signal transduction pathways. Therefore, if a constitutively activated mutant of an AKT family member is introduced into a somatic cell, the level of a downstream signal factor can be efficiently increased. For example, since AKT family members are activated by localizing to the membrane, constitutive activation of the target factor can be achieved by adding a membrane localization signal sequence to the N-terminus or C-terminus of the target factor. Type mutants can be made.
- myristoylated signal sequence for example, myristoylated signal sequence ⁇ (MGSSKSKPKDPSQRRRRIRT; SEQ ID NO: 30) derived from c-Src
- myristoylated signal sequence ⁇ MMSSKSKPKDPSQRRRRIRT; SEQ ID NO: 30
- Myr-AKT1 Myr-AKT1 in Example 8
- Other constitutively activated mutants include, for example, the PI3 kinase mutant in which the 40th glutamic acid of AKT1 is replaced with lysine (E40K-AKT1), and the PI3 kinase mutant in which the 17th glutamic acid of AKT1 is replaced with lysine Body (E17K-AKT1) and the like, but is not limited thereto.
- S6K protein is usually converted into an activated form by phosphorylation of 389th threonine, but it is reported that 389th is converted to glutamic acid and is constantly activated. . If such a constitutively activated mutant of S6K protein is introduced into a somatic cell, the activated S6K protein level can be efficiently increased.
- downstream signal factor of Ras target factor (effector) used in the present invention and the activator of this signal may be any one of the above Ras unless the downstream signal transduction pathway is constitutively inactivated.
- amino acid sequences of the downstream signal factor of the target factor (effector) and the activator of this signal one or more, preferably 1-20, more preferably 1-10, and even more preferably 1-number (5, It may be a protein comprising an amino acid sequence in which 4, 3, 2) amino acids are substituted, deleted, inserted or added.
- the downstream signal factor of the constitutively activated Ras target factor (effector) used in the present invention and the activator of this signal are preferably AKT family members or constitutively activated variants of S6K, Examples include Myr-AKT1, Myr-AKT2, Myr-AKT3, S6K1 T389E and the like used in Examples described later.
- Ras activator When receptor tyrosine kinase is activated by stimulation of extracellular signals such as growth factors, it undergoes autophosphorylation and recognizes this via adapter proteins such as Grb2 and Shc. Sos, RasGRF, RasGRF2, RasGRP, SmgGDS, Vav, C3G and the like are recruited to the cell membrane, thereby activating Ras protein localized in the cell membrane. Therefore, introduction of RasGEF or adapter protein into somatic cells can also improve iPS cell establishment efficiency through activation of Ras protein.
- Sos protein examples include mouse Sos1 (RefSeq Accession No. NP_033257), human Sos1 (RefSeq Accession No. NP_005624), mouse Sos2 (RefSeq Accession No. XP_127051), human Sos2 (RefSeq Accession No. NP_008870), or others. Orthologs thereof in mammals, natural allelic variants, polymorphic variants, splicing variants, natural and artificial activated variants, and the like. Although it is desirable to use the same type of Sos depending on the animal species of the somatic cell to be introduced, heterogeneous Sos can also be used. Examples of artificial activated mutants include membrane-localized mutants in which a Caax motif is added to the C-terminus or a myristoylation signal is added to the N-terminus.
- RasGEF proteins such as RasGRF, RasGRF2, RasGRP, SmgGDS, Vav and C3G are known, and their polymorphic variants and splicing variants are also known.
- activated mutants of these proteins include membrane-localized mutants in which a Caax motif is added to the C-terminus or a myristoylation signal is added to the N-terminus.
- Grb2 protein examples include mouse Grb2 (RefSeq Accession No. NP_032189), human Grb2 (RefSeq Accession No. NP_002077), their orthologs in other mammals, and their natural allelic variants and polymorphisms. Variants, splicing variants, natural and artificial activated mutants, and the like. Although it is desirable to use the same kind of Grb2 depending on the animal species of the somatic cell to be introduced, heterologous Grb2 can also be used. Examples of artificial activated mutants include membrane-localized mutants in which a Caax motif is added to the C-terminus or a myristoylation signal is added to the N-terminus.
- the protein of (b1) to (b4) (sometimes referred to as “the proteinaceous establishment efficiency improving factor of the present invention”) is, for example, a human or other mammalian rabbit (eg, mouse, rat, monkey, pig, dog, etc.) Cells / tissues [eg, thymus, bone marrow, spleen, brain, spinal cord, heart, skeletal muscle, kidney, lung, liver, pancreas or prostate cells / tissue, precursor cells of these cells, stem cells or cancer cells, etc.] Although it can be isolated using a known protein separation and purification technique, preferably, cDNA is cloned from the cells / tissues according to a conventional method and expressed in an appropriate host cell to prepare a recombinant protein.
- the above-mentioned various activated mutants can be prepared by introducing a point mutation or adding a membrane localization signal sequence to the terminal by a gene recombination technique known per se.
- Introduction of the proteinaceous establishment efficiency improving factor of the present invention into a somatic cell can be carried out using a method for introducing protein into a cell known per se.
- a method for introducing protein into a cell known per se examples include a method using a protein introduction reagent, a method using a protein introduction domain (PTD) or a cell-penetrating peptide (CPP) fusion protein, and a microinjection method.
- a method using a protein introduction reagent a method using a protein introduction domain (PTD) or a cell-penetrating peptide (CPP) fusion protein, and a microinjection method.
- PTD protein introduction domain
- CPP cell-penetrating peptide
- Protein introduction reagents include cationic lipid-based BioPOTER Protein Delivery Reagent (Gene Therapy Systmes), Pro-Ject TM Protein Transfection Reagent (PIERCE) and ProVectin (IMGENEX), and lipid-based Profect-1 (Targeting Systems) ), Penetrain Peptide (Q biogene) and Chariot Kit (Active Motif) based on membrane-permeable peptides, GenomONE (Ishihara Sangyo) using HVJ envelope (inactivated Sendai virus), and the like are commercially available.
- the introduction can be carried out according to the protocol attached to these reagents, but the general procedure is as follows.
- the proteinaceous establishment efficiency improving factor of the present invention is diluted in an appropriate solvent (for example, a buffer solution such as PBS or HEPES), added with an introduction reagent, and incubated at room temperature for about 5 to 15 minutes to form a complex. Is added to cells exchanged in serum-free medium and incubated at 37 ° C. for 1 to several hours. Thereafter, the medium is removed and replaced with a serum-containing medium.
- an appropriate solvent for example, a buffer solution such as PBS or HEPES
- CPP derived from PTD include polyarginine such as 11R (Cell Stem Cell, 4: 381-384 (2009)) and 9R (Cell Stem Cell, 4: 472-476 (2009)).
- the fusion protein expression vector incorporating the cDNA encoding the proteinaceous establishment efficiency improving factor of the present invention and the PTD sequence or CPP sequence is prepared and recombinantly expressed, and the fusion protein is recovered and used for introduction. Introduction can be performed in the same manner as described above except that no protein introduction reagent is added.
- Microinjection is a method in which a protein solution is put into a glass needle having a tip diameter of about 1 ⁇ m and puncture is introduced into a cell, and the protein can be reliably introduced into the cell.
- electroporation method in addition, electroporation method, semi-intact cell method (Kano, F. et al. Methods in Molecular Biology, Vol. 322, 357-365 (2006)), introduction method using Wr-t peptide (Kondo, E. et al. Protein introduction methods such as Mol. Cancer Ther. 3 (12), 1623-1630 (2004)) can also be used.
- the protein introduction operation can be performed any number of one or more times (for example, 1 to 10 times or 1 to 5 times), and preferably the introduction operation is performed 2 or more times (for example, 3 or 4 times). ) Can be done repeatedly. Examples of the interval when the introduction operation is repeated include 6 to 48 hours, preferably 12 to 24 hours.
- Proteinaceous establishment efficiency improving factor of the present invention (Ras family member, Ras target factor (effector), downstream signal factor of Ras target factor (effector)),
- the nucleic acid encoding the signal activator and Ras activator) (also referred to as “the nucleic acid establishment efficiency improving factor of the present invention”) is a Ras family member (eg, HRas, KRas, NRas, ERas, etc.), Ras target factors (effectors) (eg, PI3 kinase, RalGEF, Raf, etc.), Ras target factors (effectors) downstream signaling factors (eg, AKT1, AKT2, AKT3, Rheb, S6K, etc.) Encodes an activator of Ras target factor (effector) downstream signal (eg, TCL1) or Ras activator (eg, RasGEF, receptor tyrosine kinase adapter protein, etc.) Not particularly limited as long as
- the nucleic acid may be DNA or RNA, or may be a DNA / RNA chimera. Preferably, DNA is used.
- the nucleic acid may be double-stranded or single-stranded. In the case of a double strand, it may be a double-stranded DNA, a double-stranded RNA or a DNA: RNA hybrid.
- the nucleic acid establishment efficiency improving factor of the present invention is, for example, a human or other mammalian sputum (eg, mouse, rat, monkey, pig, dog, etc.) sputum cell / tissue [eg, thymus, bone marrow, spleen, brain, spinal cord, It can be cloned from cDNA derived from heart, skeletal muscle, kidney, lung, liver, pancreas or prostate cells / tissue, precursor cells of these cells, stem cells, cancer cells, etc.] according to a conventional method.
- mammalian sputum eg, mouse, rat, monkey, pig, dog, etc.
- sputum cell / tissue eg, thymus, bone marrow, spleen, brain, spinal cord, It can be cloned from cDNA derived from heart, skeletal muscle, kidney, lung, liver, pancreas or prostate cells / tissue, precursor cells of these cells, stem cells, cancer cells,
- the nucleic acid encoding HRas includes, for example, a nucleic acid containing the base sequence represented by SEQ ID NO: 1 or 3, or a stringent condition with a complementary strand sequence of the base sequence represented by SEQ ID NO: 1 or 3. And a nucleic acid encoding a protein that can activate at least one of the three signal transduction pathways downstream of Ras, preferably the PI3 kinase pathway and / or the Ral pathway.
- the nucleic acid encoding KRas includes, for example, a nucleic acid containing the nucleotide sequence represented by SEQ ID NO: 5 or 7, or a stringent condition with a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 5 or 7 And a nucleic acid encoding a protein that can activate at least one of the three signal transduction pathways downstream of Ras, preferably the PI3 kinase pathway and / or the Ral pathway.
- the nucleic acid encoding NRas includes, for example, a nucleic acid containing the nucleotide sequence represented by SEQ ID NO: 9 or 11, or a stringent condition with a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 9 or 11. And a nucleic acid encoding a protein that can activate at least one of the three signal transduction pathways downstream of Ras, preferably the PI3 kinase pathway and / or the Ral pathway.
- the nucleic acid encoding ERas includes, for example, a nucleic acid containing the nucleotide sequence represented by SEQ ID NO: 13 or 15, or a stringent condition with a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 13 or 15 And a nucleic acid encoding a protein that can activate at least one of the three signal transduction pathways downstream of Ras, preferably the PI3 kinase pathway and / or the Ral pathway.
- nucleic acid encoding the catalytic subunit (p110) of PI3 kinase for example, a nucleic acid encoding p110 ⁇ containing the base sequence represented by SEQ ID NO: 18 or 20, or represented by SEQ ID NO: 18 or 20 Examples thereof include a nucleic acid that encodes a protein that contains a base sequence that can hybridize with a complementary strand sequence of the base sequence under stringent conditions and that can activate the PI3 kinase pathway.
- a nucleic acid containing a cDNA sequence of mouse p110 ⁇ (RefSeq Accession No. NM_029094), human p110 ⁇ (RefSeq Accession No.
- NM_006219 mouse p110 ⁇ (RefSeq Accession No. NM_001029837), human p110 ⁇ (RefSeq Accession No. NM_005026), or Examples thereof include a nucleic acid that contains a base sequence that can hybridize under stringent conditions with a complementary strand sequence of the cDNA sequence and encodes a protein that can activate the PI3 kinase pathway.
- nucleic acid encoding RalGEF examples include a nucleic acid encoding RalGDS containing the nucleotide sequence represented by SEQ ID NO: 22 or 24, or a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 22 or 24 and a string.
- examples include a nucleic acid encoding a protein that contains a base sequence that can hybridize under a gentle condition and that can activate the Ral pathway.
- cDNA sequences of mouse Rgl RefSeqSAccession No. NM_016846
- human Rgl RefSeq Accession No. NM_015149
- mouse Rlf / Rgl2 RefSeq Accession No.
- NM_009059 human Rlf / Rgl2 (RefSeq Accession No. NM_004761)
- a nucleic acid encoding a protein that contains a base sequence that can hybridize under stringent conditions with a complementary strand sequence of the cDNA sequence and that can activate the Ral pathway.
- nucleic acid encoding Raf examples include a nucleic acid encoding c-Raf containing the nucleotide sequence represented by SEQ ID NO: 26 or 28, or a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 26 or 28 And a nucleic acid encoding a protein that contains a base sequence that can hybridize under stringent conditions and can activate the MAP kinase pathway.
- mouse A-Raf (RefSeq Accession No. NM_009703), human A-Raf (RefSeq Accession No. NM_001654), mouse B-Raf (RefSeq Accession No.
- NM_139294 human B-Raf (RefSeq Accession No. NM_004333) Examples include a nucleic acid containing a cDNA sequence, or a nucleic acid encoding a protein that contains a base sequence that can hybridize with a complementary strand sequence of the cDNA sequence under stringent conditions and can activate the MAP kinase pathway.
- nucleic acids encoding Sos include mouse Sos1 (RefSeq Accession No. NM_009231), human Sos1 (RefSeq Accession No. NM_005633), mouse Sos2 (RefSeq Accession No. XM_127051), human Sos2 (RefSeq Accession No. NM_006939)
- Examples thereof include a nucleic acid containing a cDNA sequence, or a nucleic acid encoding a protein that contains a base sequence that can hybridize with a complementary strand sequence of the cDNA sequence under stringent conditions and can activate a Ras protein.
- RasGEF cDNA sequences such as RasGRF, RasGRF2, RasGRP, SmgGDS, Vav, C3G are known, and their polymorphic variants and splicing variants are also known.
- nucleic acid encoding Grb2 examples include a nucleic acid containing the cDNA sequence of mouse Grb2 (RefSeq Accession No. NM_008163), human Grb2 (RefSeq Accession No. ⁇ NM_002086), or a stringent condition with a complementary strand sequence of the cDNA sequence.
- examples thereof include a nucleic acid that contains a base sequence that can hybridize underneath, encodes a protein that recognizes and binds to a receptor tyrosine kinase, and that can recruit RasGEF to the cell membrane to activate the Ras protein.
- nucleic acid encoding AKT1 as an example of the AKT family member include a nucleic acid containing the base sequence represented by SEQ ID NO: 34 or 36, or a complementary strand sequence of the base sequence represented by SEQ ID NO: 34 or 36 And a nucleic acid encoding a protein that contains a base sequence that can hybridize under stringent conditions and that can activate the AKT pathway.
- the nucleic acid encoding Rheb is, for example, a nucleic acid containing the base sequence represented by SEQ ID NO: 38 or 40, or a stringent condition with a complementary strand sequence of the base sequence represented by SEQ ID NO: 38 or 40 And a nucleic acid that encodes a protein that contains a base sequence that can be hybridized with and that can activate a downstream mTOR pathway.
- the nucleic acid encoding TCL1 includes, for example, a nucleic acid containing the nucleotide sequence represented by SEQ ID NO: 42 or 44, or a stringent condition with a complementary strand sequence of the nucleotide sequence represented by SEQ ID NO: 42 or 44 And a nucleic acid encoding a protein that contains a base sequence that can be hybridized with AKT1 and that can activate the AKT1 protein.
- the nucleic acid encoding S6K includes, for example, a nucleic acid containing the base sequence represented by SEQ ID NO: 46 or 48, or a stringent condition with a complementary strand sequence of the base sequence represented by SEQ ID NO: 46 or 48 And a nucleic acid encoding a protein that contains a base sequence that can be hybridized with and that can activate the S6K protein.
- nucleic acid capable of hybridizing under stringent conditions with a complementary strand sequence of the base sequence represented by each SEQ ID NO: about 80% or more, preferably about 90% or more, with the base sequence represented by each SEQ ID NO: More preferably, a nucleic acid containing a base sequence having about 95% or more identity is used.
- stringent conditions include, for example, the conditions described in Current Protocols in Molecular Biology, John Wiley and Sons, 6.3.1-6.3.6, 1999, for example, 6 ⁇ SSC (sodium chloride / sodium citrate) / 45 ° C. Hybridization, followed by one or more washes at 0.2 ⁇ SSC / 0.1% SDS / 50 to 65 ° C., those skilled in the art will know the conditions for hybridization that will give the same stringency. It can be selected appropriately.
- the protein establishment efficiency improving factor of the present invention is preferably a constant activation molecule of Ras protein, a constant activation molecule of Ras target factor (effector), or a constant signal factor downstream of Ras target factor An activated molecule, an activation molecule of downstream signal of Ras target factor, and a constant activation molecule of Ras activator. Therefore, the nucleic acid establishment efficiency improving factor of the present invention is preferably a nucleic acid encoding the above-mentioned constitutively activated molecule.
- the nucleic acid can be obtained by introducing a desired amino acid substitution into the nucleic acid encoding the wild-type molecule obtained as described above by site-directed mutagenesis, or an oligonucleotide encoding a membrane localization signal sequence. It can be prepared by adding to the end using ligase or PCR.
- the introduction of the nucleic acid establishment efficiency improving factor of the present invention into a somatic cell can be carried out by using a gene transfer method into a cell known per se.
- Ras protein, Ras target factor, downstream signal factor of Ras target factor, activator of the signal or nucleic acid encoding Ras activator should be put into an appropriate expression vector containing a promoter that can function in the host somatic cell Inserted.
- expression vectors include retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes viruses, Sendai virus and other viral vectors, animal cell expression plasmids (eg, pA1-11, pXT1, pRc / CMV, pRc / RSV). , PcDNAI / Neo) or the like.
- the type of vector to be used can be appropriately selected according to the intended use of the iPS cells obtained.
- adenovirus vectors plasmid vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, Sendai virus vectors and the like can be used.
- Examples of the promoter used in the expression vector include EF1 ⁇ promoter, CAG promoter, SR ⁇ promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (rous sarcoma virus) promoter, MoMuLV (Molone murine leukemia virus) LTR. HSV-TK (herpes simplex virus thymidine kinase) promoter and the like are used. Of these, EF1 ⁇ promoter, CAG promoter, MoMuLV LTR, CMV promoter, SR ⁇ promoter and the like are preferable.
- the expression vector may contain an enhancer, a poly A addition signal, a selection marker gene, an SV40 replication origin, and the like as desired.
- the selection marker gene include a dihydrofolate reductase gene, a neomycin resistance gene, a puromycin resistance gene, and the like.
- Ras protein, Ras target factor, downstream signal factor of Ras target factor, activator of the signal or nucleic acid encoding Ras activator may be incorporated into the expression vector alone or one or more reprogramming genes And may be incorporated into one expression vector. In some cases, it is preferable to select the former when using a retrovirus or lentiviral vector with high gene transfer efficiency, and when using a plasmid, adenovirus, episomal vector, or the like, but there is no particular limitation.
- Ras protein, Ras target factor, downstream signal factor of Ras target factor, nucleic acid encoding the signal activator or Ras activator and one or more reprogramming genes in one expression vector When incorporated, these multiple genes can be incorporated into the expression vector, preferably via sequences that allow polycistronic expression.
- sequences enabling polycistronic expression include 2A sequences of foot-and-mouth disease virus (PLoS ONE3, e2532, 2008, Stem Cells 25, 1707, 2007), IRES sequences (US Patent No. 4,937,190), preferably 2A An array can be used.
- An expression vector containing a Ras protein, a Ras target factor, a downstream signal factor of the Ras target factor, an activator of the signal or a nucleic acid encoding the Ras activator can be obtained by a method known per se depending on the type of the vector. Can be introduced.
- a virus produced in the culture supernatant by introducing a plasmid containing the nucleic acid into an appropriate packaging cell (eg, Plat-E cell) or a complementary cell line (eg, 293 cell) The vector is collected and cells are infected with the vector by an appropriate method according to each viral vector.
- WO2007 / 69666 Cell, 126, 663-676 (2006) and Cell, 131, 861-872 (2007).
- the case of use is disclosed in Science, 318, 1917-1920 (2007) 2007.
- Ras protein, Ras target factor, downstream signal factor of Ras target factor, expression of the signal activator or Ras activator (reactivation) or Activation of endogenous genes present in the vicinity where these exogenous nucleic acids are incorporated may increase the risk of carcinogenesis in tissues regenerated from differentiated cells derived from iPS cells, so Ras protein, Ras target factor or The nucleic acid encoding the Ras activator is preferably not transiently expressed in the cell chromosome. From this point of view, it is preferable to use an adenovirus vector that rarely integrates into the chromosome. Specific means using an adenoviral vector is described in Science, 322, 945-949 (2008).
- adeno-associated virus also has a low frequency of integration into chromosomes, and has lower cytotoxicity and inflammation-inducing action than adenovirus vectors, and thus can be mentioned as another preferred vector.
- the Sendai virus vector can exist stably outside the chromosome, and can be preferably used in the same manner because it can be decomposed and removed by siRNA as necessary.
- the Sendai virus vector those described in J. Biol. Chem., 282, 27383-27391 (2007) and Japanese Patent No. 3602058 can be used.
- a method of excising nucleic acid encoding Ras protein, Ras target factor or Ras activator at the time point can be preferably used. That is, loxP sequences are arranged at both ends of the nucleic acid, and after iPS cells are induced, Cre recombinase is allowed to act on the cells using a plasmid vector or an adenovirus vector to cut out the region sandwiched between the loxP sequences. be able to.
- the enhancer-promoter sequence in the LTR ⁇ U3 region may up-regulate nearby host genes by insertion mutation, so the 3′-self is deleted or replaced with a polyadenylation sequence such as SV40.
- an inactivated (SIN) LTR is used to avoid expression control of the endogenous gene by an LTR outside the loxP sequence that is not excised and remains in the genome. Specific means using Cre-loxP system and SIN LTR are disclosed in Soldner et al., Cell, 136: 964-977 (2009), Chang et al., Stem Cells, 27: 1042-1049 (2009), etc. ing.
- plasmid vector which is a non-viral vector
- the vector is transferred to cells using lipofection method, liposome method, electroporation method, calcium phosphate coprecipitation method, DEAE dextran method, microinjection method, gene gun method, etc.
- lipofection method liposome method
- electroporation method calcium phosphate coprecipitation method
- DEAE dextran method microinjection method
- gene gun method etc.
- Specific means using a plasmid as a vector are described in, for example, Science, 322, 949-953 (2008).
- gene introduction can be carried out any number of one or more times (for example, 1 to 10 times or 1 to 5 times).
- time for example, 1 to 10 times, or 1 to 5 times, etc.
- the number of times can be performed, and preferably the introduction operation can be repeated 2 times or more (for example, 3 times or 4 times).
- Preferred transposons include, for example, piggyBac, which is a transposon derived from a lepidopteran insect. Specific means using the piggyBac transposon are disclosed in Kaji, K. et al., Nature, 458: 771-775 (2009), Woltjen et al., Nature, 458: 766-770 (2009).
- Another preferred non-integrated vector is an episomal vector capable of autonomous replication outside the chromosome. Specific means using an episomal vector is disclosed in Yu et al., Science, 324, 797-801 (2009). If necessary, encode Ras protein, Ras target factor or Ras activator on episomal vector with loxP sequences placed in the same direction on the 5 'and 3' sides of vector elements necessary for episomal vector replication An expression vector into which the nucleic acid to be inserted is inserted can be constructed and introduced into somatic cells.
- the episomal vector examples include a vector containing a sequence necessary for autonomous replication derived from EBV, SV40 or the like as a vector element.
- vector elements necessary for autonomous replication include a replication origin and a gene encoding a protein that binds to the replication origin and controls replication.
- EBV the replication origin oriP And EBNA-1 gene
- SV40 includes the origin of replication ori and SV40 large T antigen gene.
- the episomal expression vector also includes a Ras protein, a Ras target factor, a downstream signal factor of the Ras target factor, a promoter that controls the transcription of a nucleic acid encoding the signal or a Ras activator.
- a promoter the same promoter as described above can be used.
- the episomal expression vector may further contain an enhancer, a poly A addition signal, a selection marker gene, and the like as desired, as described above. Examples of the selection marker gene include a dihydrofolate reductase gene and a neomycin resistance gene.
- the loxP sequence used in the present invention includes a wild-type loxP sequence derived from bacteriophage P1 (SEQ ID NO: 31), and when placed in the same direction at a position sandwiching a vector element required for transgene replication. Any mutated loxP sequence that can undergo recombination to delete sequences between loxP sequences. Examples of mutant loxP sequences include lox71 (SEQ ID NO: 32) having a mutation in the 5 ′ repeat sequence, lox66 (SEQ ID NO: 33) having a mutation in the 3 ′ repeat sequence, lox2272 having a mutation in the spacer portion, and the like. For example, lox511.
- the two loxP sequences arranged on the 5 ′ side and 3 ′ side of the vector element may be the same or different, but in the case of a mutant loxP sequence having a mutation in the spacer portion (for example, , Lox2272 and lox511) are used.
- a mutant loxP sequence eg, lox71
- a mutant loxP sequence eg, lox66
- the loxP sequence remaining on the chromosome as a result of recombination has double mutations in the 5 'and 3' repeats, making it difficult to recognize by Cre recombinase, and chromosomal deletion mutations due to unnecessary recombination. The risk of causing this is reduced.
- any of the mutant loxP sequences may be arranged on the 5 ′ side and 3 ′ side of the vector element, but the mutation site is mutated so that the mutation site is located at the outer end of the loxP sequence. It is necessary to insert the loxP sequence.
- the two loxP sequences are located 5 'and 3' to the vector element required for transgene replication (ie, the origin of replication or a gene sequence that binds to the origin of replication and encodes a protein that controls replication). Arranged in the same direction.
- the vector element sandwiched by the loxP sequence may be either one of the replication origin, the gene sequence encoding the protein that binds to the replication origin and controls replication, or both.
- Episomal vectors can be introduced into cells using, for example, lipofection method, liposome method, electroporation method, calcium phosphate coprecipitation method, DEAE dextran method, microinjection method, gene gun method and the like. Specifically, for example, the method described in Science, 324: 797-801 (2009) can be used.
- nuclear reprogramming substance refers to an iPS cell derived from a somatic cell by introducing it into a somatic cell or by bringing it into contact with a somatic cell together with the establishment efficiency improving factor of the present invention.
- a substance (group) capable of inducing the protein it may be composed of any substance such as a protein factor or a nucleic acid encoding the same (including a form incorporated in a vector) or a low molecular weight compound.
- the nuclear reprogramming substance is a protein factor or a nucleic acid encoding the same
- the following combinations are preferably exemplified (in the following, only the name of the protein factor is described).
- (1) Oct3 / 4, Klf4, c-Myc (2) Oct3 / 4, Klf4, c-Myc, Sox2 (where Sox2 can be replaced with Sox1, Sox3, Sox15, Sox17 or Sox18.
- Klf4 can be replaced with Klf1, Klf2 or Klf5.
- c-Myc can be replaced with T58A (active mutant) or L-Myc.) (3) Oct3 / 4, Klf4, c-Myc, Sox2, Fbx15, Nanog, ERas, TclI (4) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, SV40 Large T antigen (SV40LT) (5) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV16 E6 (6) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV16 E7 (7) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, HPV6 E6, HPV16 E7 (8) Oct3 / 4, Klf4, c-Myc, Sox2, TERT, Bmil (See WO 2007/069666 for the above (however, in the combination of (2) above, for the substitution of Sox2 to Sox18 and the substitution of Klf4 to K
- Oct family members such as Oct1A and Oct6 can be used instead of Oct3 / 4.
- Sox family members such as Sox7 can be used instead of Sox2 (or Sox1, Sox3, Sox15, Sox17, Sox18).
- L-Myc or Lin28B can be used instead of c-Myc or Lin28, respectively.
- combinations not including the above (1) to (24) but including all of the constituent elements in any of them and further including any other substances are also included in the category of “nuclear reprogramming substances” in the present invention.
- somatic cells subject to nuclear reprogramming are partially expressing the components in any of the above (1)-(24) under conditions that are endogenously expressed at a sufficient level for nuclear reprogramming.
- a combination of only the remaining components excluding the component can also be included in the category of “nuclear reprogramming substance” in the present invention.
- At least one selected from Oct3 / 4, Sox2, Klf4, c-Myc or L-Myc, Nanog, Lin28 or Lin28B and SV40LT, preferably two or more, more preferably three or more are examples of preferred nuclear reprogramming materials.
- a combination of reprogramming factors that do not use c-Myc is preferable when the obtained iPS cells are used for therapeutic purposes.
- a combination including a combination and not including c-Myc can be exemplified.
- Mouse and human cDNA sequence information for each of the protein factors described above can be obtained by referring to NCBI accession numbers described in WO62007 / 069666 (Nanog is described as “ECAT4” in the publication)
- mouse and human cDNA sequence information of Lin28, Lin28B, Esrrb, Esrrg, and L-Myc can be obtained by referring to the following NCBI accession numbers, respectively, and those skilled in the art can easily obtain these cDNAs. It can be isolated.
- the obtained cDNA is inserted into an appropriate expression vector, introduced into a host cell, and cultured from the resulting culture. Can be prepared by recovering.
- a nucleic acid encoding a protein factor is used as a nuclear reprogramming substance
- the obtained cDNA is treated with a virus vector, episomal vector or plasmid in the same manner as the nucleic acid establishment efficiency improving factor of the present invention.
- An expression vector is constructed by inserting it into a vector, and is subjected to a nuclear reprogramming step. If necessary, the above Cre-loxP system or piggyBac transposon system can also be used.
- each nucleic acid may be carried on a separate vector, or a plurality of nucleic acids connected in tandem to a polycistronic vector It can also be. In the latter case, in order to enable efficient polycistronic expression, it is desirable to link the 2A self-cleaving peptide of foot-and-mouth disease virus between each nucleic acid (see Science, 322, 949-953, 2008, etc.) .
- the nuclear reprogramming substance When the nuclear reprogramming substance is contacted with a somatic cell, (a) when the substance is a proteinous factor, (b) the substance is (a) in the same manner as the protein establishment efficiency improving factor of the present invention.
- the substance In the case of a nucleic acid encoding a protein factor, it can be carried out in the same manner as the nucleic acid establishment efficiency improving factor of the present invention.
- HDAC histone deacetylase
- VPA valproic acid
- TSA trichostatin A
- SSA sodium butyrate
- MC 1293, M344 nucleic acids
- siRNA and shRNA against HDAC eg, HDAC1 siRNA Smartpool® (Millipore), HuSH 29mer shRNA Constructs against HDAC1 (OriGene)) Sexual expression inhibitors, etc.
- DNA methyltransferase inhibitors for example, 5'-azacytidine5 (5'azaC)
- G9a histone methyltransferase inhibitors For example, small molecule inhibitors such as BIX-01294 (Cell Stem Cell, 2: 525-528 (2008)), nucleic acids such as siRNA and shRNA against G9a (eg, G9a siRNA (human) (Santa Cruz Biotechnology), etc.) Expression inhibitors, etc.], L-channel calcium agonist (eg Bayk8644) (Cell Stem Cell, 3, 568-574 (2008)), p53 inhibitors (eg, siRNA against p53, shRNA, dominant negative, etc.
- small molecule inhibitors such as BIX-01294 (Cell Stem Cell, 2: 525-528 (2008)
- nucleic acids such as siRNA and shRNA against G9a (eg, G9a siRNA (human) (Santa Cruz Biotechnology), etc.) Expression inhibitors, etc.
- L-channel calcium agonist eg Bayk8644
- p53 inhibitors eg, siRNA against p53, shRNA, dominant
- the nucleic acid expression inhibitor may be in the form of an expression vector containing DNA encoding siRNA or shRNA.
- SV40 large T is not an essential factor for somatic cell nuclear reprogramming, but is an auxiliary factor. It can also be included in a category.
- auxiliary factors other than those essential for nuclear reprogramming are positioned as nuclear reprogramming substances or substances that improve the establishment efficiency of iPS cells. It may be convenient.
- the nuclear reprogramming process of somatic cells is regarded as an overall event caused by the contact of somatic cells with the nuclear reprogramming substance and the substance that improves the establishment efficiency of iPS cells. There will be no gender.
- the contact of the substance that improves the efficiency of establishment of iPS cells with the somatic cell is determined depending on whether the substance is (a) a proteinaceous factor or (b) a nucleic acid encoding the proteinous factor.
- Each efficiency improvement factor can be implemented by the same method as described above.
- contact of the substance with somatic cells can be achieved by dissolving the factor in an aqueous or non-aqueous solvent at an appropriate concentration and isolating it from a human or other mammal.
- Medium suitable for culturing cultured somatic cells eg, minimal essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, 199 medium, F12 medium (about 5 to 20 if KSR is not used as an improvement factor) Etc.
- MEM minimal essential medium
- DMEM Dulbecco's modified Eagle medium
- RPMI1640 medium 199 medium
- F12 medium about 5 to 20 if KSR is not used as an improvement factor
- Etc. eg, minimal essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, 199 medium, F12 medium (about 5 to 20 if KSR is not used as an improvement factor) Etc.
- the contact period is not particularly limited as long as it is sufficient to achieve somatic cell nuclear reprogramming.
- the contact period can be allowed to coexist in the medium until a positive colony appears.
- An iPS cell establishment efficiency improving substance containing the establishment efficiency improving factor of the present invention is a nuclear reprogramming substance as long as iPS cell establishment efficiency from somatic cells is significantly improved as compared to the absence of the substance. You may make it contact with a somatic cell simultaneously, and you may make either contact first.
- the nuclear reprogramming substance is a nucleic acid encoding a proteinous factor
- the substance that improves the establishment efficiency of iPS cells is a chemical inhibitor
- the former removes the proteinous factor from the gene transfer treatment.
- a substance that improves the establishment efficiency of iPS cells is added to the medium can do.
- both a nuclear reprogramming substance and an iPS cell establishment efficiency improving substance are used in the form of a viral vector or a plasmid vector, both may be introduced into a cell simultaneously.
- the “hypoxic condition” means that the oxygen concentration in the atmosphere when cells are cultured is significantly lower than that in the air. Specifically, the oxygen concentration condition is lower than the oxygen concentration in the atmosphere of 5-10% CO 2 / 95-90% air generally used in normal cell culture. For example, oxygen in the atmosphere Conditions with a concentration of 18% or less apply.
- the oxygen concentration in the atmosphere is 15% or less (eg, 14% or less, 13% or less, 12% or less, 11% or less, etc.), 10% or less (eg, 9% or less, 8% or less, 7% or less) 6% or less), or 5% or less (eg, 4% or less, 3% or less, 2% or less, etc.).
- the oxygen concentration in the atmosphere is preferably 0.1% or more (eg, 0.2% or more, 0.3% or more, 0.4% or more), 0.5% or more (eg, 0.6% or more, 0.7% or more, 0.8% or more, 0.95 Or 1% or more (eg, 1.1% or more, 1.2% or more, 1.3% or more, 1.4% or more, etc.).
- a method for creating a hypoxic state in the cell environment is not particularly limited, but a method of culturing the cells in a CO 2 incubator in which the oxygen concentration can be adjusted is the easiest and is a preferable example.
- CO 2 incubators with adjustable oxygen concentration are sold by various equipment manufacturers (for example, CO for low oxygen culture by manufacturers such as Thermo scientific, Ikemoto Rika Kogyo, Toji Field, and Waken Pharmaceutical Co., Ltd.) 2 incubators can be used).
- the time when cell culture is started under hypoxic conditions is not particularly limited as long as it does not prevent the iPS cell establishment efficiency from being improved compared to the case of normal oxygen concentration (20%). Although it may be before contact with the establishment efficiency improving factor of the invention and the nuclear reprogramming substance, simultaneously with the contact, or after the contact, Low immediately after contact with remedial factor and nuclear reprogramming substance or after a period of time (eg 1 to 10 (eg 2,3,4,5,6,7,8 or 9) days) after contact It is preferable to culture under oxygen conditions.
- the period for culturing cells under hypoxic conditions is not particularly limited as long as it does not prevent the establishment efficiency of iPS cells from being improved compared to the case of normal oxygen concentration (20%). Examples include, but are not limited to, a period of 7 days or more, 10 days or more, 50 days or less, 40 days or less, 35 days or less, or 30 days or less.
- a preferable culture period under low oxygen conditions varies depending on the oxygen concentration in the atmosphere, and those skilled in the art can appropriately adjust the culture period according to the oxygen concentration used. In one embodiment, when selection of iPS cell candidate colonies is performed using drug resistance as an index, it is preferable to return from a low oxygen condition to a normal oxygen concentration before drug selection is started.
- the preferred time and preferred culture period for starting cell culture under hypoxic conditions vary depending on the type of nuclear reprogramming substance used, iPS cell establishment efficiency under normoxic conditions, and the like.
- the cells are suitable for culturing ES cells, for example. Can be cultured under different conditions. In the case of mouse cells, Leukemia Inhibitory Factor (LIF) is added to a normal medium as a differentiation inhibitory factor and cultured. On the other hand, in the case of human cells, it is usually desirable to add basic fibroblast growth factor (bFGF) and / or stem cell factor (SCF) instead of LIF.
- LIF Leukemia Inhibitory Factor
- bFGF basic fibroblast growth factor
- SCF stem cell factor
- the cells are cultured as feeder cells in the presence of mouse embryonic fibroblasts (MEFs) that have been treated with radiation or antibiotics to stop cell division.
- MEFs mouse embryonic fibroblasts
- STO cells are usually used as MEFs, but SNL cells (McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990)) are often used to induce iPS cells.
- Co-culture with feeder cells may be started before the contact with the establishment efficiency improving factor of the present invention and the nuclear reprogramming substance, at the time of the contact, or after the contact (for example, after 1-10 days). You may start.
- the selection of iPS cell candidate colonies includes a method using drug resistance and reporter activity as indicators and a method using visual morphological observation.
- Examples of the former include a drug resistance gene and / or a gene locus that is specifically highly expressed in differentiated pluripotent cells (for example, Fbx15, Nanog, Oct3 / 4, etc., preferably Nanog or Oct3 / 4).
- a recombinant cell targeted with a reporter gene is used to select colonies positive for drug resistance and / or reporter activity.
- Such recombinant cells include, for example, mice (Takahashi & Yamanaka, Cell, 126,-663-676) in which the ⁇ geo (encoding a fusion protein of ⁇ -galactosidase and neomycin phosphotransferase) gene is knocked in at the Fbx15 locus. 2006)) derived from transgenic mice (Okita et al., Nature, 448, 313-317 (2007)) in which a green fluorescent protein (GFP) gene and a puromycin resistance gene are incorporated into the Nanog locus Such as MEF and TTF.
- GFP green fluorescent protein
- examples of a method for selecting candidate colonies by visual morphological observation include the methods described in Takahashi et al., Cell, 131, 861-872-8 (2007).
- a method using a reporter cell is simple and efficient, when iPS cells are produced for the purpose of human therapeutic use, visual colony selection is desirable from the viewpoint of safety.
- the resulting iPS cell is a new cell different from the conventionally known iPS cell in that it contains the exogenous nucleic acid.
- the exogenous nucleic acid is introduced into a somatic cell using a retrovirus, a lentivirus or the like, the exogenous nucleic acid is usually incorporated into the genome of the resulting iPS cell, and therefore contains the exogenous nucleic acid. This trait is stably maintained.
- iPS cells are induced using somatic cells collected from the patient or another person who has the same or substantially the same type of HLA
- the desired cells ie, the organ in which the patient is affected
- Stem cell therapy by autotransplantation is possible, in which cells and cells that exhibit therapeutic effects on diseases are differentiated and transplanted into the patient.
- functional cells differentiated from iPS cells eg, hepatocytes
- drug candidates It can also be suitably used for in vitro screening of the efficacy and toxicity of compounds.
- Example 1 Examination of the effect of Ras family on human iPS cell establishment It was examined whether the Ras family (Nras, Hras, Kras and Eras) had an effect on the establishment of iPS cells.
- lentivirus The mouse ecotropic virus receptor Slc7a1 gene was expressed using pLenti6 / UbC-Slc7a1.
- the following genes were introduced into the cells (1 ⁇ 10 5 cells / well, 6 well plate) by retrovirus. The number of iPS cell colonies generated was compared with the case of introducing 4 genes (Oct3 / 4, Sox2, Klf4, c-Myc).
- V12 refers to a constant active mutant of HRas in which the 12th glycine of HRas is replaced with valine. V12 is known to activate any of the three signal transduction pathways of Ras, the MAP kinase pathway, the PI3 kinase pathway, and the Ral pathway (RalGEF pathway).
- SVLS is an inactive mutant that is unable to localize to the cell membrane by substituting SVLS for the C-terminal 4 amino acids CVLS of H-Ras
- SSVA is the C of E-Ras. It is an inactive mutant whose localization to the cell membrane is disabled by replacing the terminal 4 amino acids CSVA with SSVA.
- the cells were collected and re-sown onto feeder cells (2.5 ⁇ 10 5 cells / 100 mm dish).
- SNL cells McMahon, AP & Bradley, A. Cell 62, 1073-1085 (1990)
- the cells were cultured in a medium obtained by adding 4 ng / ml recombinant human bFGF (WAKO) to a primate ES cell culture medium (ReproCELL).
- WAKO 4 ng / ml recombinant human bFGF
- ReproCELL primate ES cell culture medium
- V12E37G is a mutant in which the Ral pathway is selectively and permanently activated by substituting the 12th glycine of HRas with valine and the 37th glutamic acid with glycine.
- the cells were collected and re-sown onto feeder cells (2.5 ⁇ 10 5 cells / 100 mm dish).
- the cells were cultured in a medium obtained by adding 4 ng / ml recombinant human bFGF (WAKO) to a primate ES cell culture medium (ReproCELL).
- WAKO recombinant human bFGF
- ReproCELL primate ES cell culture medium
- Example 3 Examination of effects on different cells Using skin-derived fibroblasts (cell name: TIG120) of a 6-year-old Japanese woman and skin-derived fibroblasts (cell name: 1616) of a 68-year-old Japanese woman The same experiment as in the above example was performed in the following combinations.
- Myr-PI3K (M-PI3K) is a constitutively active PI3 kinase localized in the membrane by adding a myristoylated signal sequence to the N-terminus.
- PI3K-CaaX (C-PI3K) is a constitutively active PI3 kinase catalytic subunit that is localized in the membrane by adding a Caax motif sequence to the C-terminus.
- the cells were collected and re-wound onto feeder cells (0.5 ⁇ 10 5 cells / 100 mm dish).
- the cells were cultured in a medium obtained by adding 4 ng / ml recombinant human bFGF (WAKO) to a primate ES cell culture medium (ReproCELL).
- WAKO human bFGF
- ReproCELL primate ES cell culture medium
- the number of iPS cell colonies on day 24 after infection is shown in FIG. Figure 3 is the average of three experiments.
- an increase in the number of human iPS cell colonies was observed by adding Eras, V12Y40C (Y40C) or V12E37G (E37G) to the 4 genes.
- Example 4 Examination of the effect of Ras signaling pathway on human iPS cell establishment (2) With respect to the effect of activation of each signal transduction pathway of Ras on the establishment of iPS cells, the same experiment as in the above Example was examined in the following combinations.
- Ras-CaaX is a constitutively activated form that has become membrane localized by adding a Caax motif sequence to the C-terminus of MAP kinase kinase kinase (MAPKKK) present in the MAP kinase pathway.
- MAPKKK MAP kinase kinase kinase
- RasGDS-Caax activates Ral, a G protein belonging to the Ras subfamily, and is permanently activated by adding a Caax motif sequence to the C-terminus of Ras target protein. Is the body.
- the cells were collected and re-sown onto feeder cells (2.5 ⁇ 10 5 cells / 100 mm dish).
- the cells were cultured in a medium obtained by adding 4 ng / ml recombinant human bFGF (WAKO) to a primate ES cell culture medium (ReproCELL).
- WAKO human bFGF
- ReproCELL primate ES cell culture medium
- Example 5 Examination of the effect of Ras signaling pathway on human iPS cell establishment (3) With respect to the effect of activation of each signal transduction pathway of Ras on the establishment of iPS cells, the same experiment as in the above Example was examined in the following combinations.
- FIG. Figure 5 shows the average of three experiments.
- V12E37G, V12Y40C, RalGDS-CaaX or PI3K-CaaX was added to the 4 genes, a marked increase in the number of human iPS cell colonies was observed.
- Example 7 Examination of effects in the absence of bFGF The effects of Raf-CaaX, RalGDS-CaaX and PI3K-CaaX in the absence of bFGF were examined. The experiment was performed in the same manner as in Examples 5 and 6. The results are shown in FIG. When RalGDS-CaaX was added to the 4 genes, the same number of colonies was observed even in the absence of bFGF as in the presence of bFGF.
- Example 8 Examination of the effect of AKT on the establishment of human iPS cells Whether cKT as a downstream signal of PI3K has an effect on the establishment of iPS cells, and c-MYC or GSK3 ⁇ influences the establishment of iPS cells by AKT Whether or not to affect.
- Myr-AKT1 is a constitutively active AKT1 localized in the membrane by adding a myristoylated signal sequence to the N-terminus.
- c-MYC shRNA is a shRNA targeting c-MYC.
- pRetrosuper Myc shRNA (Plasmid 15662) purchased from Addgene was used.
- GSK3 ⁇ S9A is a constitutively active mutant that is not degraded by protease by substituting the 9th serine of GSK3 ⁇ with alanine.
- FIG. 8A shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- the number of human iPS cell colonies was significantly increased by adding Myr-AKT1.
- c-MYC shRNA since this effect was not obtained by adding c-MYC shRNA, it was shown that c-MYC is essential for the promotion of iPS cell establishment by activation of AKT1.
- GSK3 ⁇ S9A was not affected, it was shown that phosphorylation of GSK3 ⁇ was not involved as a downstream signal of AKT1.
- HDF human skin cell-derived fibroblasts
- P110-KD is an inactivated PI3K that is a mutant lacking the kinase domain.
- AKT1-KD is an inactivated AKT1 that is a mutant lacking the kinase domain.
- PTEN ⁇ shRNA is shRNA against PTEN (phosphatase and tensin homolog) that suppresses the PI3K pathway
- pMKO.1 puro PTEN shRNA (Plasmid 10669) purchased from Addgene was used.
- FIG. 8B shows the result of measuring the number of iPS cell colonies on the seventh day after infection.
- Example 2 In the same manner as in Example 1, the following genes were introduced into skin cell-derived fibroblasts (HDF: cell name 1616) in the presence of each low molecular weight compound.
- HDF skin cell-derived fibroblasts
- PS48 is a drug that selectively binds to the PIF binding pocket site of PDK1 and activates PDK1.
- 10 ⁇ M was added to the medium. Used from Sigma.
- CHIR99021 is an inhibitor showing a high selectivity for GSK3 ⁇ .
- 1 ⁇ M was purchased from Stemgent and added to the medium.
- Wnt3a was purchased from R & D Systems, and 10 ng / ml was added to the medium.
- FIG. 9 shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- the number of human iPS cell colonies was significantly increased by adding PS48 and Wnt3a. On the other hand, when CHIR99021 was added, the number of iPS cell colonies tended to decrease. From the above, it was shown that the PDK1 and Wnt signals downstream of the PI3K signal are involved in promoting the establishment of iPS cells, but the inhibition of GSK3 ⁇ phosphorylation is not involved in the establishment of iPS cells.
- Example 10 Examination of effects of AKT family and mTOR signal on human iPS cell establishment The same genes as described above in Example 1 were introduced into skin cell-derived fibroblasts (HDF: cell name 1616).
- PTEN ⁇ shRNA is shRNA against PTEN (phosphatase and tensin homolog) that suppresses the PI3K pathway
- pMKO.1 puro PTEN shRNA (Plasmid 10669) purchased from Addgene was used.
- Myr-AKT1 # 2 is a constitutively activated AKT1 with a different basic skeleton plasmid from Myr-AKT1.
- AKT1 K179M is an inactive dominant negative AKT1 in which the kinase region is mutated.
- Myr-AKT2 is a constitutively active AKT2 that is localized in the membrane by adding a myristoylated signal sequence to the N-terminus.
- Myr-AKT3 is a constitutively active AKT3 that is localized in the membrane by adding a myristoylated signal sequence to the N-terminus.
- Myr-SGK1 is an important regulatory factor in the mTORC2 / SGK1 pathway and the addition of a myristoylated signal sequence to the N-terminus of SGK1 (Serum / glucocorticoid regulated kinase), a protein kinase in the insulin signal transduction system. It is a constitutively active SGK1 localized in the membrane.
- SGK1 K127M is a dominant negative type SGK1 in which the kinase region is mutated by replacing the 127th lysine of SGK1 with methionine.
- Myr-ILK is a localization of the membrane by adding a myristoylated signal sequence to the N-terminus of ILK (Integrin Linked Kinase), a serine / threonine kinase located upstream of AKT in the PI3K signal. It is a constitutively active ILK. ILK inhibits the PI3K / AKT pathway by binding to PDK upstream of AKT.
- ILK Integrin Linked Kinase
- ILKILE359K is a dominant negative ILK in which the kinase region is mutated by substituting the 359th glutamic acid of ILK with lysine.
- Myr-PDK1 is a constitutively active PDK1 localized in the membrane by adding a myristoylated signal sequence to the N-terminus of PDK1 contained in the PDK subfamily.
- S6K1389T389E is a constitutively active S6K1 mutant by replacing the 389th threonine of S6K1 with glutamic acid.
- FIG. 10 shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- Example 3 an increase in the number of iPS cell colonies was observed by adding p110-Caax. Similarly, an increase in the number of iPS cell colonies was also observed in PTEN shRNA, indicating that PI3K is important for promoting the establishment of iPS cells. As in Example 8, an increase in the number of iPS cell colonies was observed with Myr-AKT1, and similar results were obtained with AKT family members AKT2 and AKT3.
- Rheb is a factor that activates mTOR
- S6K1 is a downstream factor of mTOR, suggesting that activation of the mTOR signaling pathway contributes to the establishment of iPS cells.
- Example 11 Examination of c-MYC of mTOR signal-related gene on human iPS cell establishment The same gene as described above in Example 1 was introduced into skin cell-derived fibroblasts (HDF: cell name 1616).
- FIG. 11A shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- the effect of promoting the establishment of iPS cells was lost by adding c-MYC shRNA, indicating that c-MYC is essential for the promotion of iPS cell establishment by these genes.
- Mock, Myr-AKT1, Rheb, S6K1 T389E and p53 shRNA were introduced into skin cell-derived fibroblasts (HDF: cell name 1616), and the intracellular protein 7 days later was collected by a conventional method, and c-MYC was obtained by Western blot.
- P-AKT, AKT, p-S6K1, S6K1, p-TSC2 and TSC2 expression levels were confirmed.
- p53 shRNA is an shRNA against p53, and the sequence described in Hong H, et al., Nature. 460: 1132-1135 (2009) was used.
- phosphorylated AKT is increased by the introduction of p53 shRNA.
- Hong H et al. Showed that inhibition of p53 promotes the establishment of iPS cells, suggesting that inhibition of p53 promotes the establishment of iPS cells through phosphorylation of AKT.
- Example 12 Examination of the effect of AKT1 on the promotion of human iPS cell establishment by the inhibition of p53 and the introduction of GLIS1
- human skin cell-derived fibroblasts HDF: cell name 1616
- HDF cell name 1616
- FIG. 12A shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- the number of iPS cell colonies was increased by adding Myr-AKT1 and p53 ⁇ ⁇ ⁇ shRNA simultaneously. Therefore, it was shown that introduction of p53shRNA and AKT1 has a synergistic effect of promoting the establishment of iPS cells. Moreover, since the number of iPS cell colonies decreased in any case by c-MYC shRNA, it was suggested that these effects are actions mediated by c-MYC.
- HDF human skin cell-derived fibroblasts
- FIG. 12B shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
- FIG. 12C shows the result of measuring the number of iPS cell colonies on the 32nd day after infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
さらに、Takahashiら(非特許文献4)は、ヒトの皮膚由来線維芽細胞にマウスと同様の4遺伝子を導入することにより、iPS細胞を樹立することに成功した。一方、Yuら(非特許文献5)は、Klf4とc-Mycの代わりにNanogとLin28を使用してヒトiPS細胞を作製した。このように、体細胞に特定因子を導入することにより、ヒト及びマウスで、分化多能性においてES細胞と遜色のないiPS細胞を作製できることが示された。
[1] 人工多能性幹細胞の樹立効率の改善方法であって、体細胞の核初期化工程において、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6Kからなる群より選択される1以上のタンパク質の活性化型のレベルを増大させることを含む、方法。
[2] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1およびS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを含む、上記[1]記載の方法。
[3] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、上記[2]記載の方法。
[4] RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、上記[2]又は[3]記載の方法。
[5] RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、上記[3]又は[4]記載の方法。
[6] RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、上記[3]又は[4]記載の方法。
[7] PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする上記[3]記載の方法。
[8] AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、上記[2]又は[3]記載の方法。
[9] AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、上記[3]又は[8]記載の方法。
[10] p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを更に含む、上記[2]記載の方法。
[11] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される因子を含有してなる、人工多能性幹細胞の樹立効率改善剤。
[12] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、上記[11]記載の剤。
[13] RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、上記[11]又は[12]記載の剤。
[14] RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、上記[12]又は[13]記載の剤。
[15] RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、上記[12]又は[13]記載の剤。
[16] PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする上記[12]記載の剤。
[17] AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、上記[11]又は[12]記載の剤。
[18] AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、上記[12]又は[17]記載の剤。
[19] p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を更に含有する、上記[11]記載の剤。
[20] 体細胞に核初期化物質と、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子とを接触させることを含む、人工多能性幹細胞の製造方法。
[21] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、上記[20]記載の方法。
[22] RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、上記[20]又は[21]記載の方法。
[23] RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、上記[21]又は[22]記載の方法。
[24] RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、上記[21]又は[22]記載の方法。
[25] PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする上記[21]記載の方法。
[26] AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、上記[20]又は[21]記載の方法。
[27] AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、上記[21]又は[26]記載の方法。
[28] p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを更に含む、上記[20]記載の方法。
[29] 核初期化物質が、Octファミリーのメンバー、Soxファミリーのメンバー、Klf4ファミリーのメンバー、Mycファミリーのメンバー、Linファミリーのメンバー及びNanog、並びにそれらをコードする核酸からなる群より選択される、上記[20]記載の方法。
[30] 核初期化物質がOct3/4、Klf4及びSox2、又はそれらをコードする核酸である、上記[20]記載の方法。
[31] 核初期化物質がOct3/4、Klf4、Sox2並びにc-Myc若しくはL-Myc及び/又はNanog及び/又はLin28若しくはLin28B、或いはそれらをコードする核酸である、上記[20]記載の方法。
[32] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される因子と、核初期化物質とを含有してなる、人工多能性幹細胞の誘導剤。
[33] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、上記[32]記載の剤。
[34] RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、上記[32]又は[33]記載の剤。
[35] RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、上記[33]又は[34]記載の剤。
[36] RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、上記[33]又は[34]記載の剤。
[37] 核初期化物質が、Octファミリーのメンバー、Soxファミリーのメンバー、Klf4ファミリーのメンバー、Mycファミリーのメンバー、Linファミリーのメンバー及びNanog、並びにそれらをコードする核酸からなる群より選択される、上記[32]記載の剤。
[38] PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする上記[33]記載の剤。
[39] AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、上記[32]又は[33]記載の剤。
[40] AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、上記[33]又は[39]記載の剤。
[41] p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を更に含有する、上記[32]記載の剤。
[42] 核初期化物質がOct3/4、Klf4及びSox2、又はそれらをコードする核酸である、上記[32]記載の剤。
[43] 核初期化物質がOct3/4、Klf4、Sox2並びにc-Myc若しくはL-Myc及び/又はNanog及び/又はLin28若しくはLin28B、或いはそれらをコードする核酸である、上記[32]記載の剤。
[44] Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1又はS6Kをコードする外来性核酸を含む、人工多能性幹細胞。
[45] 前記外来性核酸がゲノムに組み込まれている、上記[44]記載の細胞。
[46] 下記の工程:
(1) 上記[20]~[31]のいずれかに記載の方法により人工多能性幹細胞を製造する工程、及び
(2) 上記工程(1)で得られた人工多能性幹細胞に分化誘導処理を行い、体細胞に分化させる工程、
を含む、体細胞の製造方法。
[47] 人工多能性幹細胞の樹立効率改善のための、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子の使用。
[48] 人工多能性幹細胞の製造のための、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子の使用であって、該因子を核初期化物質とともに体細胞に接触させることを特徴とする、使用。
[49] 体細胞の製造における、上記[44]又は[45]記載の人工多能性幹細胞の使用。
[50] 体細胞の製造における細胞ソースとしての、上記[44]又は[45]記載の人工多能性幹細胞。
本発明においてiPS細胞作製のための出発材料として用いることのできる体細胞は、哺乳動物(例えば、ヒト、マウス、サル、ウシ、ブタ、ラット、イヌ等)由来の生殖細胞以外のいかなる細胞であってもよく、例えば、角質化する上皮細胞(例、角質化表皮細胞)、粘膜上皮細胞(例、舌表層の上皮細胞)、外分泌腺上皮細胞(例、乳腺細胞)、ホルモン分泌細胞(例、副腎髄質細胞)、代謝・貯蔵用の細胞(例、肝細胞)、境界面を構成する内腔上皮細胞(例、I型肺胞細胞)、内鎖管の内腔上皮細胞(例、血管内皮細胞)、運搬能をもつ繊毛のある細胞(例、気道上皮細胞)、細胞外マトリックス分泌用細胞(例、線維芽細胞)、収縮性細胞(例、平滑筋細胞)、血液と免疫系の細胞(例、Tリンパ球)、感覚に関する細胞(例、桿細胞)、自律神経系ニューロン(例、コリン作動性ニューロン)、感覚器と末梢ニューロンの支持細胞(例、随伴細胞)、中枢神経系の神経細胞とグリア細胞(例、星状グリア細胞)、色素細胞(例、網膜色素上皮細胞)、及びそれらの前駆細胞(組織前駆細胞)等が挙げられる。細胞の分化の程度や細胞を採取する動物の齢などに特に制限はなく、未分化な前駆細胞(体性幹細胞も含む)であっても、最終分化した成熟細胞であっても、同様に本発明における体細胞の起源として使用することができる。ここで未分化な前駆細胞としては、たとえば神経幹細胞、造血幹細胞、間葉系幹細胞、歯髄幹細胞等の組織幹細胞(体性幹細胞)が挙げられる。
本明細書において「活性化型Rasタンパク質のレベルを増大させる物質」とは、Rasファミリーに属する1以上のタンパク質において、活性化型(GTP結合型)として存在するタンパク質レベルを増大させることができるものであれば、いかなる物質であってもよい。すなわち、Rasタンパク質やそれをコードする核酸自体や、Rasタンパク質を不活性化型(GDP結合型)から活性化型に変換させる反応(GDP-GTP交換反応)を促進するか、或いはRasタンパク質を活性化型から不活性化型に変換させる反応(GTP加水分解反応)を阻害することにより、結果的に活性化型のRasタンパク質レベルを増大させる物質も、本明細書における「活性化型Rasタンパク質のレベルを増大させる物質」に含まれる。
本明細書における「Rasファミリーメンバー」とは、癌原遺伝子として同定されたHRas、KRas、NRasとの一次構造上の相同性により同定されたRasサブファミリータンパク質のうち、Raf、PI3キナーゼ及びRalGEFから選ばれる1以上の分子、好ましくはPI3キナーゼ及び/又はRalGEFを標的因子とし、活性化型Rasタンパク質の作用により上記因子の下流のシグナル伝達経路(即ち、Raf/MAPキナーゼ経路(MAPキナーゼ経路)、PI3キナーゼ経路、Ral経路)を活性化しうるタンパク質を意味する。好ましいRasファミリーメンバーの例としては、HRas、KRas、NRas、ERas等が挙げられるが、これらに限定されない。
本発明で用いられる「Rasの標的因子(エフェクター)」としては、PI3キナーゼ、RalGEF及びRafが挙げられる。
本発明で用いられる「Rasの標的因子(エフェクター)の下流シグナル因子」としては、AKTファミリーメンバー、Rheb及びS6Kが挙げられ、「Rasの標的因子(エフェクター)の下流シグナルの活性化因子」としては、TCL1が挙げられる。
受容体チロシンキナーゼが増殖因子などの細胞外シグナルの刺激を受けて活性化されると自己リン酸化を起こし、これを認識するGrb2やShcなどのアダプタータンパク質を介してRasGEFであるSos、RasGRF、RasGRF2、RasGRP、SmgGDS、Vav、C3G等が細胞膜にリクルートされ、それによって細胞膜に局在するRasタンパク質が活性化される。従って、RasGEFやアダプタータンパク質を体細胞に導入することによっても、Rasタンパク質の活性化を介してiPS細胞の樹立効率を改善することができる。
本発明のタンパク性樹立効率改善因子(Rasファミリーメンバー、Rasの標的因子(エフェクター)、Rasの標的因子(エフェクター)の下流シグナル因子、そのシグナルの活性化因子及びRas活性化因子)をコードする核酸(「本発明の核酸性樹立効率改善因子」という場合もある)は、上記した本発明におけるRasファミリーメンバー(例、HRas、KRas、NRas、ERas等)、Rasの標的因子(エフェクター)(例、PI3キナーゼ、RalGEF、Raf等)、Rasの標的因子(エフェクター)の下流シグナル因子(例、AKT1、AKT2、AKT3、Rheb、S6K等)、Rasの標的因子(エフェクター)の下流シグナルの活性化因子(例、TCL1等)又はRas活性化因子(例、RasGEF、受容体チロシンキナーゼアダプタータンパク質等)をコードするものであれば特に制限はない。該核酸はDNAであってもRNAであってもよく、あるいはDNA/RNAキメラであってもよい。好ましくはDNAが挙げられる。また、該核酸は二本鎖であっても、一本鎖であってもよい。二本鎖の場合は、二本鎖DNA、二本鎖RNAまたはDNA:RNAのハイブリッドでもよい。
本発明において「核初期化物質」とは、体細胞に導入することにより、あるいは本発明の樹立効率改善因子と共に体細胞に接触させることにより、該体細胞からiPS細胞を誘導することができる物質(群)であれば、タンパク性因子またはそれをコードする核酸(ベクターに組み込まれた形態を含む)、あるいは低分子化合物等のいかなる物質から構成されてもよい。核初期化物質がタンパク性因子またはそれをコードする核酸の場合、好ましくは以下の組み合わせが例示される(以下においては、タンパク性因子の名称のみを記載する)。
(1) Oct3/4, Klf4, c-Myc
(2) Oct3/4, Klf4, c-Myc, Sox2(ここで、Sox2はSox1, Sox3, Sox15, Sox17またはSox18で置換可能である。また、Klf4はKlf1, Klf2またはKlf5で置換可能である。さらに、c-MycはT58A(活性型変異体), L-Mycで置換可能である。)
(3) Oct3/4, Klf4, c-Myc, Sox2, Fbx15, Nanog, ERas, TclI
(4) Oct3/4, Klf4, c-Myc, Sox2, TERT, SV40 Large T antigen(以下、SV40LT)
(5) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV16 E6
(6) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV16 E7
(7) Oct3/4, Klf4, c-Myc, Sox2, TERT, HPV6 E6, HPV16 E7
(8) Oct3/4, Klf4, c-Myc, Sox2, TERT, Bmil
(以上、WO 2007/069666を参照(但し、上記(2)の組み合わせにおいて、Sox2からSox18への置換、Klf4からKlf1もしくはKlf5への置換については、Nature Biotechnology, 26, 101-106 (2008)を参照)。「Oct3/4, Klf4, c-Myc, Sox2」の組み合わせについては、Cell, 126, 663-676 (2006)、Cell, 131, 861-872 (2007) 等も参照。「Oct3/4, Klf2(またはKlf5), c-Myc, Sox2」の組み合わせについては、Nat. Cell Biol., 11, 197-203 (2009) も参照。「Oct3/4, Klf4, c-Myc, Sox2, hTERT, SV40LT」の組み合わせについては、Nature, 451, 141-146 (2008)も参照。)
(9) Oct3/4, Klf4, Sox2(Nature Biotechnology, 26, 101-106 (2008)を参照)
(10) Oct3/4, Sox2, Nanog, Lin28(Science, 318, 1917-1920 (2007)を参照)
(11) Oct3/4, Sox2, Nanog, Lin28, hTERT, SV40LT(Stem Cells, 26, 1998-2005 (2008)を参照)
(12) Oct3/4, Klf4, c-Myc, Sox2, Nanog, Lin28(Cell Research (2008) 600-603を参照)
(13) Oct3/4, Klf4, c-Myc, Sox2, SV40LT(Stem Cells, 26, 1998-2005 (2008)も参照)
(14) Oct3/4, Klf4(Nature 454:646-650 (2008)、Cell Stem Cell, 2:525-528(2008)を参照)
(15) Oct3/4, c-Myc(Nature 454:646-650 (2008)を参照)
(16) Oct3/4, Sox2 (Nature, 451, 141-146 (2008), WO2008/118820を参照)
(17) Oct3/4, Sox2, Nanog (WO2008/118820を参照)
(18) Oct3/4, Sox2, Lin28 (WO2008/118820を参照)
(19) Oct3/4, Sox2, c-Myc, Esrrb (ここで、EsrrbはEsrrgで置換可能である。Nat. Cell Biol., 11, 197-203 (2009) を参照)
(20) Oct3/4, Sox2, Esrrb (Nat. Cell Biol., 11, 197-203 (2009) を参照)
(21) Oct3/4, Klf4, L-Myc (Proc. Natl. Acad. Sci. USA., 107, 14152-14157 (2010) を参照)
(22) Oct3/4, Nanog
(23) Oct3/4 (Cell 136: 411-419 (2009)、Nature, 08436, doi:10.1038 published online(2009))
(24) Oct3/4, Klf4, c-Myc, Sox2, Nanog, Lin28, SV40LT(Science, 324: 797-801 (2009)を参照)
Lin28 NM_145833 NM_024674
Lin28b NM_001031772 NM_001004317
Esrrb NM_011934 NM_004452
Esrrg NM_011935 NM_001438
L-Myc NM_008506 NM_001033081
従来iPS細胞の樹立効率が低いために、近年、その効率を改善する物質が種々提案されている。よって前記本発明の樹立効率改善因子に加え、他の樹立効率改善物質を体細胞に接触させることにより、iPS細胞の樹立効率をより高めることが期待できる。
体細胞の核初期化工程において低酸素条件下で細胞を培養することにより、iPS細胞の樹立効率をさらに改善することができる(Cell Stem Cell., 5(3): 237-241 (2009); WO2010/013845を参照)。本明細書において「低酸素条件」とは、細胞を培養する際の雰囲気中の酸素濃度が、大気中のそれよりも有意に低いことを意味する。具体的には、通常の細胞培養で一般的に使用される5-10% CO2/95-90%大気の雰囲気中の酸素濃度よりも低い酸素濃度の条件が挙げられ、例えば雰囲気中の酸素濃度が18%以下の条件が該当する。好ましくは、雰囲気中の酸素濃度は15%以下(例、14%以下、13%以下、12%以下、11%以下など)、10%以下(例、9%以下、8%以下、7%以下、6%以下など)、または5%以下(例、4%以下、3%以下、2%以下など)である。また、雰囲気中の酸素濃度は、好ましくは0.1%以上(例、0.2%以上、0.3%以上、0.4%以上など)、0.5%以上(例、0.6%以上、0.7%以上、0.8%以上、0.95以上など)、または1%以上(例、1.1%以上、1.2%以上、1.3%以上、1.4%以上など)である。
本発明の樹立効率改善因子と核初期化物質(および他のiPS細胞の樹立効率改善物質)とを接触させた後、細胞を、例えばES細胞の培養に適した条件下で培養することができる。マウス細胞の場合、通常の培地に分化抑制因子としてLeukemia Inhibitory Factor(LIF)を添加して培養を行う。一方、ヒト細胞の場合には、通常、LIFの代わりに塩基性線維芽細胞増殖因子(bFGF)および/または幹細胞因子(SCF)を添加することが望ましい。しかしながら、本発明の樹立効率改善因子を体細胞に接触させた場合、bFGFの非存在下でもbFGF存在下と同程度のヒトiPS細胞コロニーを得ることができる。
このようにして樹立されたiPS細胞は、種々の目的で使用することができる。例えば、ES細胞などの多能性幹細胞で報告されている分化誘導法(例えば、神経幹細胞への分化誘導法としては、特開2002-291469、膵幹様細胞への分化誘導法としては、特開2004-121165、造血細胞への分化誘導法としては、特表2003-505006に記載される方法などがそれぞれ例示される。この他にも、胚葉体の形成による分化誘導法としては、特表2003-523766に記載の方法などが例示される。)を利用して、iPS細胞から種々の細胞(例、心筋細胞、血液細胞、神経細胞、血管内皮細胞、インスリン分泌細胞等)への分化を誘導することができる。したがって、患者本人やHLAの型が同一もしくは実質的に同一である他人から採取した体細胞を用いてiPS細胞を誘導すれば、そこから所望の細胞(即ち、該患者が罹病している臓器の細胞や疾患に対する治療効果を発揮する細胞など)に分化させて該患者に移植するという、自家移植による幹細胞療法が可能となる。さらに、iPS細胞から分化させた機能細胞(例、肝細胞)は、対応する既存の細胞株よりも実際の生体内での該機能細胞の状態をより反映していると考えられるので、医薬候補化合物の薬効や毒性のin vitroスクリーニング等にも好適に用いることができる。
Rasファミリー(Nras、Hras、Kras及びEras)がiPS細胞の樹立に効果を及ぼすか否かを検討した。
2) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Hras
3) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Kras
4) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Eras
5) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12
6) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, SVLS
7) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, SSVA
8) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, N17
Rasのシグナル伝達経路であるMAPキナーゼ経路、PI3キナーゼ経路、及びRal経路(RalGEF経路)の3つの経路のうち、いずれのシグナル伝達経路の活性化がiPS細胞樹立に効果を及ぼすのか検討を行った。実験は以下の組み合わせを用い、実施例1と同様の手法で行った。
2) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Hras
3) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Kras
4) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Eras
5) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12
6) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12T35S
7) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12E37G
8) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12Y40C
6歳の日本人女性の皮膚由来線維芽細胞(細胞名:TIG120)及び68歳の日本人女性の皮膚由来線維芽細胞(細胞名:1616)を用いて、前記実施例と同様の実験を以下の組み合わせで行った。
2) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12Y40C (図3では単に「Y40C」と表記)
3) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Myr-PI3K(図3では単に「M-PI3K」と表記)
4) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, PI3K-CaaX(図3では単に「C-PI3K」と表記)
5) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12E37G (図3では単に「E37G」と表記)
Rasの各シグナル伝達経路の活性化がiPS細胞樹立に及ぼす効果につき、前記実施例と同様の実験を以下の組み合わせで検討した。
2) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Hras
3) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Kras
4) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Eras
5) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12T35S
6) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12E37G
7) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Raf-CaaX
8) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, RalGDS-CaaX
Rasの各シグナル伝達経路の活性化がiPS細胞樹立に及ぼす効果につき、前記実施例と同様の実験を以下の組み合わせで検討した。
2) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, N17 (図5では「HRasN17」と表記)
3) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12T35S(図5では「HRasV12/S35」と表記)
4) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12E37G(図5では「HRasV12/G37」と表記)
5) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, V12Y40C(図5では「HRasV12/C40」と表記)
6) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, Raf-CaaX
7) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, RalGDS-CaaX
8) ヒト由来のOct3/4, Sox2, Klf4, c-Myc, PI3K-CaaX(図5では「p110-CaaX」と表記)
iPS細胞の樹立において、PI3キナーゼ経路、Ral経路およびMAPキナーゼ経路がそれぞれ相互に関連しているのか、それとも独立した経路であるのかを検討した。
bFGF非存在下でのRaf-CaaX、RalGDS-CaaXおよびPI3K-CaaXの効果を検討した。実験は実施例5や6と同様にして行った。結果を図7に示す。4遺伝子にRalGDS-CaaXを加えた場合に、bFGF非存在下でもbFGF存在下と同程度のコロニー数が観察された。
PI3Kの下流シグナルとしてのAKTがiPS細胞の樹立に効果を及ぼすか否か、およびAKTによるiPS細胞の樹立にc-MYCまたはGSK3βが影響を及ぼすか否かを検討した。
2) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
3) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA
5) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, GSK3β S9A
2) ヒト由来のOct3/4, Sox2, Klf4, p110-Caax
3) ヒト由来のOct3/4, Sox2, Klf4, p110-KD
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
5) ヒト由来のOct3/4, Sox2, Klf4, AKT1-KD
6) ヒト由来のOct3/4, Sox2, Klf4, PTEN shRNA
7) ヒト由来のOct3/4, Sox2, Klf4, TCL1
AKT関連のシグナル(PDK1、GSK3β、Wnt)がiPS細胞の樹立効率に及ぼす影響を検討した。
2) ヒト由来のOct3/4, Sox2, Klf4, CHIR99021
3) ヒト由来のOct3/4, Sox2, Klf4, Wnt3a
前記実施例1と同様に皮膚細胞由来線維芽細胞(HDF:細胞名1616)へ以下の遺伝子を導入した。
2) ヒト由来のOct3/4, Sox2, Klf4, p110-Caax
3) ヒト由来のOct3/4, Sox2, Klf4, PTEN shRNA
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
5) ヒト由来のOct3/4, Sox2, Klf4, AKT1 K179M
6) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1#2
7) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT2
8) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT3
9) ヒト由来のOct3/4, Sox2, Klf4, Myr-SGK1
10) ヒト由来のOct3/4, Sox2, Klf4, SGK1 K127M
11) ヒト由来のOct3/4, Sox2, Klf4, Myr-ILK
12) ヒト由来のOct3/4, Sox2, Klf4, ILK E359K
13) ヒト由来のOct3/4, Sox2, Klf4, Myr-PDK1
14) ヒト由来のOct3/4, Sox2, Klf4, GSK3 S9A
15) ヒト由来のOct3/4, Sox2, Klf4, Rheb
16) ヒト由来のOct3/4, Sox2, Klf4, S6K1 T389E
17) ヒト由来のOct3/4, Sox2, Klf4, FKBP12
前記実施例1と同様に皮膚細胞由来線維芽細胞(HDF:細胞名1616)へ以下の遺伝子を導入した。
2) ヒト由来のOct3/4, Sox2, Klf4, Mock, c-MYC shRNA
3) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA
5) ヒト由来のOct3/4, Sox2, Klf4, Rheb
6) ヒト由来のOct3/4, Sox2, Klf4, Rheb, c-MYC shRNA
7) ヒト由来のOct3/4, Sox2, Klf4, S6K1 T389E
8) ヒト由来のOct3/4, Sox2, Klf4, S6K1 T389E, c-MYC shRNA
いずれの場合でも、c-MYC shRNAを加えることでiPS細胞の樹立促進効果がなくなることから、これらの遺伝子によるiPS細胞の樹立促進にはc-MYCが必須であることが示された。
Myr-AKT1、RhebおよびS6K1 T389Eの導入によりc-MYCの発現量が上昇したことが確認された。このことより、Myr-AKT1、RhebおよびS6K1 T389Eはc-MYCの発現上昇を介してiPS細胞の樹立促進を行っている機序が示唆された。
前記実施例1と同様にヒト皮膚細胞由来線維芽細胞(HDF:細胞名1616)へ以下の遺伝子を導入した。
2) ヒト由来のOct3/4, Sox2, Klf4, Mock, p53 shRNA
3) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, p53 shRNA
5) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA
6) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA, p53 shRNA
7) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA
8) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA, p53 shRNA
2) ヒト由来のOct3/4, Sox2, Klf4, Mock, GLIS1
3) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, GLIS1
5) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA
6) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA, GLIS1
7) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA
8) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA, GLIS1
Myr-AKT1およびGLIS1を同時に加えることで、iPS細胞コロニー数の増加が認められた。従って、GLIS1とAKT1の導入はiPS細胞の樹立促進の相乗効果を有することが示された。また、c-MYC shRNAによりいずれの場合でも、iPS細胞コロニー数が減少したことから、これらの効果はc-MYCを介した作用であることが示唆された。
2) ヒト由来のOct3/4, Sox2, Klf4, Mock, p53 shRNA
3) ヒト由来のOct3/4, Sox2, Klf4, Mock, GLIS1
4) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, Mock
5) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, p53 shRNA
6) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, GLIS1
7) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA, Mock
8) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA, p53 shRNA
9) ヒト由来のOct3/4, Sox2, Klf4, c-MYC shRNA, GLIS1
10) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA, Mock
11) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA, p53 shRNA
12) ヒト由来のOct3/4, Sox2, Klf4, Myr-AKT1, c-MYC shRNA, GLIS1
Claims (50)
- 人工多能性幹細胞の樹立効率の改善方法であって、体細胞の核初期化工程において、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6Kからなる群より選択される1以上のタンパク質の活性化型のレベルを増大させることを含む、方法。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを含む、請求項1記載の方法。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、請求項2記載の方法。
- RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、請求項2又は3記載の方法。
- RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、請求項3又は4記載の方法。
- RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、請求項3又は4記載の方法。
- PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする請求項3記載の方法。
- AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、請求項2又は3記載の方法。
- AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、請求項3又は8記載の方法。
- p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを更に含む、請求項2記載の方法。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される因子を含有してなる、人工多能性幹細胞の樹立効率改善剤。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、請求項11記載の剤。
- RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、請求項11又は12記載の剤。
- RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、請求項12又は13記載の剤。
- RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、請求項12又は13記載の剤。
- PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする請求項12記載の剤。
- AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、請求項11又は12記載の剤。
- AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、請求項12又は17記載の剤。
- p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を更に含有する、請求項11記載の剤。
- 体細胞に核初期化物質と、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子とを接触させることを含む、人工多能性幹細胞の製造方法。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、請求項20記載の方法。
- RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、請求項20又は21記載の方法。
- RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、請求項21又は22記載の方法。
- RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、請求項21又は22記載の方法。
- PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする請求項21記載の方法。
- AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、請求項20又は21記載の方法。
- AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、請求項21又は26記載の方法。
- p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を体細胞に接触させることを更に含む、請求項20記載の方法。
- 核初期化物質が、Octファミリーのメンバー、Soxファミリーのメンバー、Klf4ファミリーのメンバー、Mycファミリーのメンバー、Linファミリーのメンバー及びNanog、並びにそれらをコードする核酸からなる群より選択される、請求項20記載の方法。
- 核初期化物質がOct3/4、Klf4及びSox2、又はそれらをコードする核酸である、請求項20記載の方法。
- 核初期化物質がOct3/4、Klf4、Sox2並びにc-Myc若しくはL-Myc及び/又はNanog及び/又はLin28若しくはLin28B、或いはそれらをコードする核酸である、請求項20記載の方法。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される因子と、核初期化物質とを含有してなる、人工多能性幹細胞の誘導剤。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー及びS6Kが恒常的活性化型である、請求項32記載の剤。
- RasファミリーメンバーがERas、HRas、NRas及びKRasからなる群より選択される、請求項32又は33記載の剤。
- RasファミリーメンバーがPI3キナーゼ経路、Ral経路及びMAPキナーゼ経路から選択される1以上のシグナル伝達経路を恒常的に活性化する、請求項33又は34記載の剤。
- RasファミリーメンバーがPI3キナーゼ経路及び/又はRal経路を恒常的に活性化する、請求項33又は34記載の剤。
- 核初期化物質が、Octファミリーのメンバー、Soxファミリーのメンバー、Klf4ファミリーのメンバー、Mycファミリーのメンバー、Linファミリーのメンバー及びNanog、並びにそれらをコードする核酸からなる群より選択される、請求項32記載の剤。
- PI3キナーゼがAKT経路のシグナル伝達経路を恒常的に活性化することを特徴とする請求項33記載の剤。
- AKTファミリーメンバーがAKT1, AKT2及びAKT3からなる群より選択される、請求項32又は33記載の剤。
- AKTファミリーメンバーがmTOR経路のシグナル伝達経路を恒常的に活性化する、請求項33又は38記載の剤。
- p53阻害薬、GLISファミリーメンバー、並びにそれらをコードする核酸からなる群より選択される1以上の因子を更に含有する、請求項32記載の剤。
- 核初期化物質がOct3/4、Klf4及びSox2、又はそれらをコードする核酸である、請求項32記載の剤。
- 核初期化物質がOct3/4、Klf4、Sox2並びにc-Myc若しくはL-Myc及び/又はNanog及び/又はLin28若しくはLin28B、或いはそれらをコードする核酸である、請求項32記載の剤。
- Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1又はS6Kをコードする外来性核酸を含む、人工多能性幹細胞。
- 前記外来性核酸がゲノムに組み込まれている、請求項44記載の細胞。
- 下記の工程:
(1) 請求項20~31のいずれか1項に記載の方法により人工多能性幹細胞を製造する工程、及び
(2) 上記工程(1)で得られた人工多能性幹細胞に分化誘導処理を行い、体細胞に分化させる工程、
を含む、体細胞の製造方法。 - 人工多能性幹細胞の樹立効率改善のための、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子の使用。
- 人工多能性幹細胞の製造のための、Rasファミリーメンバー、PI3キナーゼ、RalGEF、Raf、AKTファミリーメンバー、Rheb、TCL1及びS6K、並びにそれらをコードする核酸からなる群より選択される1以上の因子の使用であって、該因子を核初期化物質とともに体細胞に接触させることを特徴とする、使用。
- 体細胞の製造における、請求項44又は45記載の人工多能性幹細胞の使用。
- 体細胞の製造における細胞ソースとしての、請求項44又は45記載の人工多能性幹細胞。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11845474.3A EP2647699B1 (en) | 2010-12-03 | 2011-12-02 | Efficient method for establishing induced pluripotent stem cells |
JP2012546966A JP6029137B2 (ja) | 2010-12-03 | 2011-12-02 | 効率的な人工多能性幹細胞の樹立方法 |
US13/991,341 US9506039B2 (en) | 2010-12-03 | 2011-12-02 | Efficient method for establishing induced pluripotent stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41932010P | 2010-12-03 | 2010-12-03 | |
US61/419,320 | 2010-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012074117A1 true WO2012074117A1 (ja) | 2012-06-07 |
WO2012074117A8 WO2012074117A8 (ja) | 2012-09-07 |
Family
ID=46172038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/077992 WO2012074117A1 (ja) | 2010-12-03 | 2011-12-02 | 効率的な人工多能性幹細胞の樹立方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9506039B2 (ja) |
EP (1) | EP2647699B1 (ja) |
JP (1) | JP6029137B2 (ja) |
WO (1) | WO2012074117A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065435A1 (en) * | 2012-10-23 | 2014-05-01 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2015025959A1 (ja) * | 2013-08-23 | 2015-02-26 | 独立行政法人理化学研究所 | 蛍光特性を示すポリペプチド、およびその利用 |
JP2022503604A (ja) * | 2018-08-28 | 2022-01-12 | ステムラボ・インコーポレイテッド | 合成メッセンジャーrnaを用いて尿細胞を神経幹細胞へ直接逆分化する方法 |
JP2023505119A (ja) * | 2019-11-29 | 2023-02-08 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | mTOR活性化剤を含む体細胞から誘導万能幹細胞への逆分化効率増進用組成物及びこれを用いた逆分化効率の増進方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017306698B2 (en) | 2016-08-04 | 2023-03-30 | Wake Forest University Health Sciences | Blood brain barrier model and methods of making and using the same |
WO2019068066A1 (en) * | 2017-09-29 | 2019-04-04 | National Health Research Institutes | METHODS AND COMPOSITIONS FOR IMPROVING THE SURVIVAL AND FUNCTIONALITY OF ANTI-TUMOR AND ANTI-VIRAL CELL LYMPHOCYTES |
US11268070B2 (en) * | 2018-04-16 | 2022-03-08 | Cellular Engineering Technologies, Inc. | Methods for creating integration-free, virus-free, exogenous oncogene-free IPS cells and compositions for use in such methods |
TW202300642A (zh) | 2021-03-25 | 2023-01-01 | 美商藍岩醫療公司 | 獲得誘導型多能幹細胞之方法 |
WO2024092120A2 (en) * | 2022-10-26 | 2024-05-02 | Sirnaomics, Inc. | Sirnas against kras and raf1 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
JP2002291469A (ja) | 2001-03-30 | 2002-10-08 | Japan Science & Technology Corp | 胚性幹細胞からの神経幹細胞、運動ニューロン及びgaba作動性ニューロンの製造法 |
JP2003505006A (ja) | 1998-06-08 | 2003-02-12 | オシリス セラピューティクス,インコーポレイテッド | ヒト間葉幹細胞の使用による造血幹細胞分化の調節 |
JP2003523766A (ja) | 2000-02-21 | 2003-08-12 | ウイスコンシン アラムニ リサーチ ファンデーション | 霊長類胚性幹細胞からの胚様体の製造方法 |
JP2004121165A (ja) | 2002-10-07 | 2004-04-22 | Asahi Kasei Corp | 膵幹様細胞の分化誘導方法 |
JP3602058B2 (ja) | 1999-05-18 | 2004-12-15 | 株式会社ディナベック研究所 | エンベロープ遺伝子欠損パラミクソ科ウイルスベクター |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2010013845A1 (en) | 2008-07-30 | 2010-02-04 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
US7955901B2 (en) | 2007-10-04 | 2011-06-07 | Infineon Technologies Ag | Method for producing a power semiconductor module comprising surface-mountable flat external contacts |
CN101550406B (zh) | 2008-04-03 | 2016-02-10 | 北京大学 | 制备多潜能干细胞的方法,试剂盒及用途 |
CA2695522C (en) * | 2008-05-02 | 2019-01-15 | Kyoto University | Method of nuclear reprogramming |
JP5340265B2 (ja) * | 2008-06-27 | 2013-11-13 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
CN102144027B (zh) | 2008-07-07 | 2016-04-06 | 宝生物工程株式会社 | 生产多能干细胞的方法 |
CN104962583B (zh) * | 2008-07-16 | 2019-11-01 | 株式会社爱迪药业 | 使用染色体非整合型病毒载体制造经初始化的细胞的方法 |
EP2253700A1 (en) * | 2009-05-13 | 2010-11-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems |
-
2011
- 2011-12-02 WO PCT/JP2011/077992 patent/WO2012074117A1/ja active Application Filing
- 2011-12-02 JP JP2012546966A patent/JP6029137B2/ja active Active
- 2011-12-02 US US13/991,341 patent/US9506039B2/en active Active
- 2011-12-02 EP EP11845474.3A patent/EP2647699B1/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
JP2003505006A (ja) | 1998-06-08 | 2003-02-12 | オシリス セラピューティクス,インコーポレイテッド | ヒト間葉幹細胞の使用による造血幹細胞分化の調節 |
JP3602058B2 (ja) | 1999-05-18 | 2004-12-15 | 株式会社ディナベック研究所 | エンベロープ遺伝子欠損パラミクソ科ウイルスベクター |
JP2003523766A (ja) | 2000-02-21 | 2003-08-12 | ウイスコンシン アラムニ リサーチ ファンデーション | 霊長類胚性幹細胞からの胚様体の製造方法 |
JP2002291469A (ja) | 2001-03-30 | 2002-10-08 | Japan Science & Technology Corp | 胚性幹細胞からの神経幹細胞、運動ニューロン及びgaba作動性ニューロンの製造法 |
JP2004121165A (ja) | 2002-10-07 | 2004-04-22 | Asahi Kasei Corp | 膵幹様細胞の分化誘導方法 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2010013845A1 (en) | 2008-07-30 | 2010-02-04 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
Non-Patent Citations (73)
Title |
---|
"2i is an inhibitor of mitogen-active protein kinase signalling and glycogen synthase kinase-3", PLOS BIOLOGY, vol. 6, no. 10, 2008, pages 2237 - 2247 |
"Current Protocols in Molecular Biology", 1999, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6 |
CELL STEM CELL, vol. 2, 2008, pages 525 - 528 |
CELL STEM CELL, vol. 3, 2008, pages 132 - 135 |
CELL STEM CELL, vol. 3, 2008, pages 475 - 479 |
CELL STEM CELL, vol. 3, 2008, pages 568 - 574 |
CELL STEM CELL, vol. 4, 2009, pages 381 - 384 |
CELL STEM CELL, vol. 4, 2009, pages 472 - 476 |
CELL STEM CELL, vol. 7, 2010, pages 651 - 655 |
CELL STEM CELL., vol. 5, no. 3, 2009, pages 237 - 241 |
CELL, 2008, pages 600 - 603 |
CELL, vol. 126, 2006, pages 663 - 676 |
CELL, vol. 131, 2007, pages 861 - 872 |
CELL, vol. 136, 2009, pages 411 - 419 |
CHANG ET AL., STEM CELLS, vol. 27, 2009, pages 1042 - 1049 |
DEROSSI, D. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 10444 - 50 |
ELMQUIST, A. ET AL., EXP. CELL RES., vol. 269, 2001, pages 237 - 44 |
FRANKEL, A. ET AL., CELL, vol. 55, 1988, pages 1189 - 93 |
GAO, C. ET AL., BIOORG. MED. CHEM., vol. 10, 2002, pages 4057 - 65 |
GREEN, M.; LOEWENSTEIN, P. M., CELL, vol. 55, 1988, pages 1179 - 88 |
HONG H ET AL., NATURE, vol. 460, 2009, pages 1132 - 1135 |
HONG, F. D.; CLAYMAN, G L., CANCER RES., vol. 60, 2000, pages 6551 - 6 |
J. BIOL. CHEM., vol. 282, 2007, pages 27383 - 27391 |
KAJI, K. ET AL., NATURE, vol. 458, 2009, pages 771 - 775 |
KANO, F. ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 322, 2006, pages 357 - 365 |
KONDO, E. ET AL., MOL. CANCER THER., vol. 3, no. 12, 2004, pages 1623 - 1630 |
LIN, Y. Z. ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 14255 - 14258 |
LUNDBERG, P. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 299, 2002, pages 85 - 90 |
MARSON A. ET AL.: "Wnt signaling promotes reprogramming of somatic cells to pluripotency", CELL STEM CELL, vol. 3, no. 2, 2008, pages 132 - 5, XP002523704 * |
MCMAHON, A.P.; BRADLEY, A., CELL, vol. 62, 1990, pages 1073 - 1085 |
MOL. CELL. BIOL. |
MORRIS, M. C. ET AL., NATURE BIOTECHNOL., vol. 19, 2001, pages 1173 - 6 |
NAKAGAWA, M. ET AL., NAT. BIOTETHNOL., vol. 26, 2008, pages 101 - 106 |
NAT. BIOTECHNOL., vol. 26, no. 7, 2008, pages 795 - 797 |
NAT. BIOTECHNOL., vol. 27, 2009, pages 459 - 461 |
NAT. CELL BIOL., vol. 11, 2009, pages 197 - 203 |
NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 101 - 106 |
NATURE, 2009, pages 08436 |
NATURE, vol. 451, 2008, pages 141 - 146 |
NATURE, vol. 454, 2008, pages 646 - 650 |
NATURE, vol. 460, 2009, pages 1132 - 1135 |
NATURE, vol. 474, 2011, pages 225 - 229 |
NOGUCHI M. ET AL.: "Proto-oncogene TCL1: more than just a coactivator for Akt", FASEB J., vol. 21, no. 10, 2007, pages 2273 - 2284, XP002453350 * |
OEHLKE, J. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1414, 1998, pages 127 - 39 |
OKITA ET AL., NATURE, vol. 448, 2007, pages 313 - 317 |
OKITA, K. ET AL., NATURE, vol. 448, 2007, pages 313 - 317 |
PARK, C. B. ET AL., PROC. NATL ACAD. SCI. USA, vol. 97, 2000, pages 8245 - 50 |
PLOS ONE, vol. 3, 2008, pages E2532 |
POOGA, M. ET AL., FASEB J., vol. 12, 1998, pages 67 - 77 |
PROC. NATL. ACAD. SCI. USA., vol. 107, 2010, pages 14152 - 14157 |
REBOLLO A. ET AL.: "Ras proteins: recent advances and new functions", BLOOD, vol. 94, no. 9, 1999, pages 2971 - 80, XP055111007 * |
RNA, vol. 14, 2008, pages 1 - 10 |
ROUSSELLE, C. ET AL., MOL. PHARMACOL., vol. 57, 2000, pages 679 - 86 |
SAWADA, M. ET AL., NATURE CELL BIOL., vol. 5, 2003, pages 352 - 7 |
SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
SCIENCE, vol. 322, 2008, pages 945 - 949 |
SCIENCE, vol. 322, 2008, pages 949 - 953 |
SCIENCE, vol. 324, 2009, pages 797 - 801 |
SOLDNER ET AL., CELL, vol. 136, 2009, pages 964 - 977 |
STEM CELLS, vol. 25, 2007, pages 1707 |
STEM CELLS, vol. 26, 2008, pages 1998 - 2005 |
TAKAHASHI ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI K. ET AL.: "Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway", J.BIOL.CHEM., vol. 280, no. 38, 2005, pages 32768 - 74, XP055111012 * |
TAKAHASHI K. ET AL.: "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", CELL, vol. 126, no. 4, 2006, pages 663 - 76, XP008157317 * |
TAKAHASHI, K. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI, K. ET AL., NATURE, vol. 423, 2003, pages 541 - 545 |
TAKAHASHI, K.; YAMANAKA, S., CELL, vol. 126, 2006, pages 663 - 676 |
TAKAHASHI; YAMANAKA, CELL, vol. 126, 2006, pages 663 - 676 |
WOLTJEN ET AL., NATURE, vol. 458, 2009, pages 766 - 770 |
YAMNIK R.L. ET AL.: "mTOR/S6Kl and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation", FEBS LETT., vol. 84, no. 1, 5 January 2010 (2010-01-05), pages 124 - 8, XP026802269 * |
YU ET AL., SCIENCE, vol. 324, 2009, pages 797 - 801 |
YU, J. ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
ZHAO Y. ET AL.: "Two supporting factors greatly improve the efficiency of human iPSC generation", CELL STEM CELL, vol. 3, no. 5, 2008, pages 475 - 9, XP008129613 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014065435A1 (en) * | 2012-10-23 | 2014-05-01 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
JP2015532088A (ja) * | 2012-10-23 | 2015-11-09 | 国立大学法人京都大学 | 効率的に人工多能性幹細胞を樹立する方法 |
US10077429B2 (en) | 2012-10-23 | 2018-09-18 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2015025959A1 (ja) * | 2013-08-23 | 2015-02-26 | 独立行政法人理化学研究所 | 蛍光特性を示すポリペプチド、およびその利用 |
JPWO2015025959A1 (ja) * | 2013-08-23 | 2017-03-02 | 国立研究開発法人理化学研究所 | 蛍光特性を示すポリペプチド、およびその利用 |
US10030055B2 (en) | 2013-08-23 | 2018-07-24 | Riken | Polypeptide exhibiting fluorescent properties, and utilization of the same |
JP2022503604A (ja) * | 2018-08-28 | 2022-01-12 | ステムラボ・インコーポレイテッド | 合成メッセンジャーrnaを用いて尿細胞を神経幹細胞へ直接逆分化する方法 |
JP2023505119A (ja) * | 2019-11-29 | 2023-02-08 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | mTOR活性化剤を含む体細胞から誘導万能幹細胞への逆分化効率増進用組成物及びこれを用いた逆分化効率の増進方法 |
JP7357978B2 (ja) | 2019-11-29 | 2023-10-10 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | mTOR活性化剤を含む体細胞から誘導万能幹細胞への逆分化効率増進用組成物及びこれを用いた逆分化効率の増進方法 |
Also Published As
Publication number | Publication date |
---|---|
US20130267030A1 (en) | 2013-10-10 |
JP6029137B2 (ja) | 2016-11-24 |
EP2647699A4 (en) | 2015-01-21 |
JPWO2012074117A1 (ja) | 2014-05-19 |
EP2647699B1 (en) | 2020-04-01 |
EP2647699A1 (en) | 2013-10-09 |
WO2012074117A8 (ja) | 2012-09-07 |
US9506039B2 (en) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5827220B2 (ja) | 人工多能性幹細胞の樹立効率改善方法 | |
JP6029137B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 | |
JP5765746B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 | |
JP5553289B2 (ja) | 新規核初期化物質 | |
JP5562231B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 | |
JP5888753B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 | |
JP5773393B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 | |
WO2012141181A1 (ja) | 核初期化物質 | |
WO2012128343A1 (ja) | 人工多能性幹細胞の樹立効率改善剤及びそれを用いた効率的な人工多能性幹細胞の樹立方法 | |
WO2011158967A1 (en) | Method for efficiently establishing induced pluripotent stem cell | |
WO2011055851A1 (en) | Method of efficiently establishing induced pluripotent stem cells | |
WO2013031826A1 (ja) | 核初期化物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11845474 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012546966 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13991341 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011845474 Country of ref document: EP |